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A Systems Approach to Cellular Signal Transduction
Abstract
Vital cellular processes such as growth, gene expression, and homeostasis depend on the correct
transmission of molecular signals within and between cells. The vast complexity of these molecular
signaling networks has necessitated the use of mathematical methods to model, characterize, and
predict cellular responses. The work presented in this dissertation shows how computational methods
were used to elucidate two clinically-relevant cellular signaling responses: (i) phosphotyrosine signaling
through the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that is commonly
overexpressed or structurally altered in human cancers; and (ii) phosphoinositide and calcium signaling in
human platelets---the key cellular mediators of hemostasis and pathological thrombus formation. The
kinetic model of EGFR-mediated signaling in wild-type and mutant cells showed how mutant forms of the
receptor use an irregular pattern of tyrosine phosphorylation that preferentially activates the survival
oncoprotein, Akt. By quantifying the amount of signal flow through diverging pathways downstream of the
receptor, our calculations provided a mechanistic explanation for the clinical observation that therapeutic
tyrosine kinase inhibitors can control tumor growth in cells bearing certain EGFR mutations. In the second
major study, a kinetic model of ADP-stimulated calcium release in human platelets was used to make
precise, quantitative predictions about the molecular makeup and structural properties of the platelet.
Specifically, we found that the resting structure of platelets places strong restrictions on several
biophysical quantities, such as the resting concentration of free inositol 1,4,5-trisphosphate, the ratio of
calcium ATPase pumps to release channels, and the size of the calcium storage compartment. Notably,
the model also demonstrated that the irregular calcium spiking behavior observed in single ADPstimulated platelets is due to the extremely small cellular volume. A novel method for constructing kinetic
signaling networks, based on restricting the steady-state properties of the model, is also presented.
Future applications and extensions of the systems approach to signal transduction modeling are
discussed in the final chapter.
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ABSTRACT

A SYSTEMS APPROACH TO CELLULAR SIGNAL TRANSDUCTION

Jeremy E. Purvis

Scott Diamond
Ravi Radhakrishnan

Vital cellular processes such as growth, gene expression, and homeostasis depend on the correct
transmission of molecular signals within and between cells. The vast complexity of these molecular
signaling networks has necessitated the use of mathematical methods to model, characterize, and
predict cellular responses. The work presented in this dissertation shows how computational methods were used to elucidate two clinically-relevant cellular signaling responses: (i) phosphotyrosine
signaling through the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that is
commonly overexpressed or structurally altered in human cancers; and (ii) phosphoinositide and
calcium signaling in human platelets—the key cellular mediators of hemostasis and pathological
thrombus formation. The kinetic model of EGFR-mediated signaling in wild-type and mutant cells
showed how mutant forms of the receptor use an irregular pattern of tyrosine phosphorylation that
preferentially activates the survival oncoprotein, Akt. By quantifying the amount of signal ﬂow
through diverging pathways downstream of the receptor, our calculations provided a mechanistic
explanation for the clinical observation that therapeutic tyrosine kinase inhibitors can control tumor growth in cells bearing certain EGFR mutations. In the second major study, a kinetic model of
ADP-stimulated calcium release in human platelets was used to make precise, quantitative predictions about the molecular makeup and structural properties of the platelet. Speciﬁcally, we found
that the resting structure of platelets places strong restrictions on several biophysical quantities,
such as the resting concentration of free inositol 1,4,5-trisphosphate, the ratio of calcium ATPase
pumps to release channels, and the size of the calcium storage compartment. Notably, the model
also demonstrated that the irregular calcium spiking behavior observed in single ADP-stimulated
platelets is due to the extremely small cellular volume. A novel method for constructing kinetic
signaling networks, based on restricting the steady-state properties of the model, is also presented.
Future applications and extensions of the systems approach to signal transduction modeling are
discussed in the ﬁnal chapter.
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Chapter 1

Introduction
The concept of signal transduction is inherently diﬃcult because it comprises the interaction among
a group of objects and not the objects themselves. One cannot simply point to a single member
of this interacting group and say: there is the signal. Rather, the signal must be understood as
a higher-level phenomenon that emerges from the coordinated interactions among the group—a
phenomenon that is more easily observed from a distance than by close examination. Under this
pretext, then, the most concrete discussion we may have about a signal pertains to its medium:
those physical entities that are coordinated in space and time to propogate the signal. For an
ocean wave, this medium is water. For cells, the signaling medium comprises a vast assortment of
biomolecules that range from relatively simple species such as water, ions, small organic molecules,
lipids, proteins, and sugars—to large macromolecular assemblies of proteins, polysaccharides, lipids,
and nucleic acids. Individually, these molecules display a wide range of physical and chemical
properties that have been fairly well documented. When organized as cellular signaling systems,
however, they form a staggering array of temporal and spatial conﬁgurations with holistic properties
that are profoundly and qualitatively diﬀerent than their molecular components. It is through these
networks of molecular interactions that cells are able to send and receive information within their
environment.

1.1

Cellular Signals

Cellular signals can be transmitted in a variety of ways. For example, the release of calcium
from intracellular stores involves the transport of calcium ions from one compartment of a cell
into another (e.g., from the endoplasmic reticulum to the cytoplasm). Once arriving in the new
compartment, the calcium ions can physically interact with a new set of biomolecules [130] and
1

alter their functional properties. In this example, the signal is carried by calcium ions through the
intracellular space and depends on biochemical interactions between enzyme and ion. By contrast,
the activation of guanine nucleotide-binding proteins (G proteins) by an extracellular hormone is
signaled through a successive relay of physical interactions proceeding from the extracellular space,
across the plasma membrane, and into the cell’s interior. Each of these interactions involves subtle
conformational changes within the extracellular ligand, the G protein-coupled receptor, neighboring
lipids within the surrounding membrane, and a host of intracellular proteins and nucleotides [101].
Unlike the release of calcium ions, this relay of events occurs without any bulk transport of the
molecules involved—a type of signaling that more closely resembles what information theorist John
Pierce describes as a “discernible indication of what is not itself directly perceptible” [125]. Whether
signals are transmited directly or indirectly, cellular signal transduction is driven by a sequence of
precisely coordinated kinetic and biophysical interactions. Studying the nature of these interactions,
on a component-by-component basis, has formed the basis of cellular signal transduction research
for the past 30 years.
Because so many vital cellular processes depend on the correct transmission of molecular signals, it
is perhaps not surprising that errors in signaling can have devastating pathalogical consequences.
In some cases, dysregulated signals are caused by a single molecular defect. As we shall see in
Chapters 2 and 3, one amino acid change in the epidermal growth factor receptor can destabilize
the receptor’s native conformation and cause changes in its pattern of autophosphorylation. These
small perturbations at the receptor level can alter the concentrations of key downstream proteins,
thwarting the cell’s normal proliferatory and survival responses. In other cases, disease phenotypes
arise from the combined eﬀect of multiple molecular alterations. For example, it is well established
that disruption of signaling pathways involved in DNA repair and DNA damage checkpoints can
lead to an increased mutational load on the cell and the accumulation of additional mutations that
cause cancer [100]. Consider the two oncogenes, c-myc and ras D . A mutation in either gene alone
does not pose an observable threat to mammalian cells; when these mutations are encountered
together, however, they can rapidly transform the cell into a malignant state [151]. Signaling
defects aﬀecting a wide range of cellular processes that lead to disease have been reported [90],
from which two fundamental observations have become universally appreciated: ﬁrst, that signaling
behaviors are driven by molecular events—which are themselves governed by the physico-chemical
properties of the molecules involved—and that alterations in the physico-chemical properties of
participating molecules can aﬀect the signaling phenotype; second, that disease phenotypes often
arise from the distortion—rather than the complete abolition—of “normal” signal transduction.
Clearly, understanding the molecular mechanisms that underly signaling behaviors is of paramount
2

importance if we are to direct signal transduction research toward the treatment and prevention
of disease. But, as we shall see, even a complete knowledge of these molecular properties is not
suﬃcient to obtain a full understanding the complexities of cellular signaling.

1.2

Emergent Properties with Molecular Causes

Thus far, we have reasoned that the logical starting point for understanding cellular signal transduction is a mechanistic description of the individual molecular events that produce an observable
signaling phenotype1 . Unfortunately, the relationship between individual molecular components
and the observable signaling phenotype they comprise is rarely straighforward. Part of this difﬁculty can be attributed to the sheer complexity of such large networks; they contain so many
“moving parts” that their behaviors cannot be predicted by intuition alone. The other diﬃculty,
which is much more subtle, is that the observable signaling behavior is often described, measured,
or conceptualized at a diﬀerent time or length scale than the molecular events that drive it. The
term emergent properties has been used to refer to such high-level patterns that arise out of the
interactions among a set of basic elements 2 . In a seminal paper appearing in Science in 1999 [13],
Bhalla and Iyengar examined a variety of well-known signaling pathways to demonstrate that interacting pathways have complex and nonintuitive emergent properties. Strikingly, their analysis
showed that—even with complete knowledge of the kinetic properties of each component in the
system—the emergent signaling behaviors were qualitatively unique and unpredictable. To help solidify the concept of emergent properties, let us now consider three examples of emergent behavior
from cellular biology:

1. Lipid vesicle. Phospholipids, such as those that comprise cellular membranes, will naturally
form spherical vesicles because of the properties of lipid membranes. The physical interactions
between neighboring lipids in the micelle can alter the ﬂuidity, spacing, and permeability of
the membrane. Thus, macroscopic properties such as the diameter of a vesicle—which may
be measured in, say, nanometers—are dependent on the chemical properties of its surfactant
molecules such as hydrophobicity, degree of saturation, and charge.
1 As an alternative strategy, many studies seek to draw statistical associations between molecular properties and
phenotypic outcomes. For example, genome wide association studies relate the occurance of a particular polymorphism to the risk for disease. While these types of correlations are useful for prediction or prognosis of disease
outcomes, they do not explain the molecular basis for the observed outcome thus cannot oﬀer any straightforward
opportunities to rationally intervene in patholical scenarios.
2 The concept of emergence is quite old and predates its application to cellular biology by over a thousand years.
See [39] for an historical overview of emergence.
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2. Molecular oscillation. In systems of interacting proteins, oscillatory behavior can result
from a negative feedback loop between two proteins. A classic example of oscillation occurs when the tumor suppressor protein p53 activates transcription of its negative regulator,
Mdm2. Mdm2, in turn, promotes degradation of p53 through ubiquitination [94]. Emergent properties of the system, such as the period of oscillation of activated p53 (measured in
hours), are depedent on the various kinetic characteristics of the system such as the rate of
protein degradation or the aﬃnity of p53 for the promoter region of Mdm2.

3. Clotting blood. The formation of a blood clot in reponse to endothelial injury is coordinated
by clotting factors in ﬂowing blood, procoagulant proteins released from the subendothelium,
and platelets. In healthy individuals, a clot must grow large enough to stop bleeding but not so
large as to occlude the vessel and obstruct ﬂowing blood. Slight alterations or deﬃciencies in
just one of these coagulation factors, such as the integrin αIIbβ3 on the surface of platelets,
can prevent normal bridging between platelets and retard formation of a stable clot [118].
Thus, macroscopic properties such as the diameter or density of a blood clot are indirectly
but intimately related to the dynamic contributions of thousands of kinetic interactions among
participating molecules.

In many cases, the emergent behavior of a system can be easily measured (e.g., the time between
p53 peak levels) whereas detailed knowledge about the basic elements in the system (kinetic rate
constants and cellular concentrations) is limited or unknown. Inferring these properties is highly
desirable but can be extremely diﬃcult. Even if one is able to reproduce, or simulate, the behavior
of the system using some nominal set of basic elements, there are usually multiple sets of nominal
elements that fulﬁll this requirement. In mathematical terms, this is known as an inverse problem
because it seeks to ﬁnd the unknown cause that produces a known consequence. In general, inverse
problems are diﬃcult to solve because they involve several (often, inﬁnite) alternative possibilities
that can each generate the same observed behavior. The standard method of solving inverse problems is quite dull: one must “try out” many diﬀerent possibilities of basic elements, simulate their
interactions, and determine which set of elements best explains the emergent behavior. Obviously,
this step is greatly aided by computer simulations, which can rapidly alter and test potential solutions. Even for relatively simple signaling networks, however, the number of possible molecular
conﬁgurations quickly becomes very large and is usually impossible to exhaustively analyze even
for the fastest computers.
4

1.3

The “Systems Approach” to Cellular Signaling

Motivated by the increasing computational power available to end users and the growing wealth of
biochemical and genetic data, various computational strategies have been employed to understand
and predict the behavior of biological signaling systems. In general, these methods fall into one of
two categories based on the intended outcome of the analysis. The ﬁrst type of analysis is intended
to make accurate predictions of a system’s behavior based on some set of initial conditions and
quantitative knowledge about the system. These type of studies are often content to establish
correlations between, say, a certain genetic mutation and an observable phenotype, or to deﬁne
disease risks associated with a given phenotype. The second type of systems approach aims to ﬁnd
a mechanistic explanation for the observed behavior of a system. Here, the ability of a model to
make accurate predictions is used to retroactively to examine the unique features of that model
that are conferring the predictive power.
One very popular method for analyzing signaling networks is ordinary diﬀerential equation (ODE)
models, [38] which provide excellent mechanistic detail for modeling time-dependent behaviors and
are particularly well-suited for kinetic systems. ODEs have been used extensively to model GPCR
dynamics [101], the ErbB family of signaling networks [86, 128], cell cycle regulation [38], and various other cellular signaling systems. ODE modeling is used extensively in this work to model signal
transduction through the epidermal growth factor receptor (Chapters 2 and 3) as well as phosphoinositide and calcium signaling in human platelets (Chapter 4). If mechanistic detail of a system
is lacking, purely “data-driven” approaches such as clustering, principal component analysis, and
partial least squares regression have been succesfully used to derive meaningful biological insights
from large data sets [73]. These methods utilize correlations between measurements within large
data sets to extract high-level processes that govern the behavior of the system. These approaches
have been used to identify groups of molecules that inﬂuence cell decisions, such as whether or
not to enter apoptosis [71]. Other statistical approaches to modeling signal transduction, such
as Bayesian network analysis [122], have been cleverly employed to discover previously unknown
interactions between signaling molecules. These methods work by methodically perturbing signals
in individual cells and looking for changes in the dependence between pairs of molecules. Finally,
graph theory and transcription factor activation assays have been combined to establish molecular regulators that connect transmembrane signaling and gene regulation [20]. In Chapter 6, we
show how artiﬁcial neural networks can be used to model cellular signal networks and contain both
topological and time-dependent features.
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1.4

Application of the Systems Approach

In the chapters that follow, we apply a computational systems approach to study two clinicallyrelevant mammalian signal transduction systems: signaling through the epidermal growth factor
receptor (EGFR), a receptor tyrosine kinase that is commonly overexpressed or structurally altered
in human cancers; and phosphoinositide and calcium signaling in human platelets—small, anucleate
cells that undergo dramatic signaling in response to vascular injury in order to stop bleeding.

1.4.1

Signaling through the Epidermal Growth Factor Receptor

The ﬁrst analysis presented in this dissertation is focused on signaling through the epidermal growth
factor receptor (EGFR/ErbB1/HER1), a receptor tyrosine kinase that activates a multilayered
signaling network mediating crucial pathways leading to cell survival, proliferation, diﬀerentiation,
and motility [180]. The ErbB signaling network is commonly dysregulated in a large fraction of
human cancers. Speciﬁcally, ErbB overexpression and/or mutation occurs in amost half of non
small-cell lung cancers (NSCLCs), which comprise the largest portion of cancer-related deaths and
will kill about a quarter of a million people in the United States this year [78]. On a molecular
level, ampliﬁcation of EGFR can lead to delayed and prolonged receptor tyrosine phosphorylation,
constitutive Akt activation [3], and resistance to anti-tumor drugs [180]. The ErbB signaling
network is arguably the most well studied signaling system from a computational systems-biological
perspective3 and has spurred a great deal of computational and conceptual advances in the ﬁeld
of systems biology that extend beyond it the scope of just the ErbB family of receptors [95]. An
enormous body of literature surrounds this receptor, its signaling, and its relationship to cancer
(reviewed by Citri and Yarden [33]).
Our eﬀort to model EGFR signaling was motivated by recent clinical evidence showing that cancer
patients who harbor certain mutations in the EGFR kinase domain have a rapid and dramatic
response to anti-tumor therapy [106, 120]. Seeking a molecular explanation for this phenomenon,
we studied the eﬀects of mutations in the EGFR tyrosine kinase domain on the receptors kinetic
behavior and downstream signaling responses [128]. Speciﬁcally, we monitored the activation of
downstream proteins Akt and ERK as indicators of preferential signaling through two phosphotyrosine residues on the EGFR C-terminal tail. By modeling signal ﬂows through these branching
pathways, we showed that the EGFR mutants had increased binding to tyrosine kinase inhibitors
(TKIs), enhanced phosphorylation of substrate tyrosine residues, and preferential activation of the
Akt signaling pathway, a critical pathway for cell growth, survival, and motility. These ﬁndings are
3 See

the “exhaustive” EGFR model constructed by Oda et al. [119]
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dicussed in detail in two subsequent chapters focusing on the multiscale aspects of the modeling
approach (Chapter 2) and the implications of preferential Akt activation on cell survival (Chapter 3). Recent thinking has likened the ErbB signaling network to a bow-tie-conﬁgured network of
dynamic interactions that display modularity, redundancy, and control circuitry [33]. Under this
framework, identifying the role and signiﬁcance of drug sensitizing mutations of ErbB receptors
would require a systems-level understanding of the signaling network [71–73] This would prove to
be of enormous value in eﬀectively designing multikinase inhibitors for the development of cancer
therapies that target several points along the signaling pathway simultaneously [48, 77].

1.4.2

Intracellular Signaling in Human Platelets

The second signaling system examined in this dissertation is the ADP-induced calcium response of
human platelets. Platelets are small, disc-shaped cell fragments that circulate innocuously in the
blood until encountering exposed endothelial tissue or activating agonists. When soluble agonists in
the blood bind to their cognate receptors on the platelet surface, this engages a host of intracellular
signaling events, including receptor activation, G protein signaling, second messenger generation,
calcium release, granule secretion, and cytoskeletal rearrangement [17]. Platelet activation plays
a centrol role in cardiovascular diesease, which is the leading cause of mortality worldwide and
accounts for 1.74 million heart attacks and strokes, 1.115 million angiograms, and 0.652 million
stent placements in the United States each year [103].
Like the epidermal growth factor receptor signaling network, platelets are also prone to aberrant
signaling. Defects in platelet signaling can lead to hemophilia or pathological thrombus formation
[57]. Pathologies of platelet receptors can impair the platelet response to a single agonist [117, 118,
131]. Defects in G-protein activation result in mild bleeding disorders, abnormal aggregation and
secretion responses to a number of agonists, or diminished GTPase activity on activation. Impaired
calcium signaling has been observed in several patients with impaired aggregation and secretion,
and has been correlated with thrombus formation [18], diabetes [166] and hypertension [47].
In Chapter 4, we address the platelet signaling response to ADP, an important agonist that triggers
platelet shape change and aggregation. Through our analysis, we quantify how various molecular
mechanisms are integrated to maintain platelet homeostasis and allow responsiveness to ADP. This
work presents the ﬁrst earnest attempt to model intracellular signaling in the platelet featured the
ADP receptor, PI metabolism, calcium release, and PKC activity. Existing kinetic information
for 77 reactions, 132 ﬁxed kinetic rate constants, and 70 species was combined with electrochemical calculations, measurements of platelet ultrastructure, novel experimental results, and published
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single-cell data. The model accurately predicted (i) steady-state resting concentrations for intracellular calcium, inositol 1,4,5-trisphosphate, diacylglycerol, phosphatidic acid, phosphatidylinositol,
phosphatidylinositol phosphate, and phosphatidylinositol 4,5-bisphosphate, (ii) transient increases
in intracellular calcium, inositol 1,4,5-trisphosphate, and GqGTP in response to ADP, and (iii) the
volume of the platelet dense tubular system. A more stringent test of the model involved stochastic simulation of individual platelets, which display an asynchronous calcium spiking behavior in
response to ADP. Simulations accurately reproduced the broad frequency distribution of measured
spiking events and demonstrated that asynchronous spiking was a consequence of stochastic ﬂuctuations due to the small volume of the platelet. The model also provided insights into possible
mechanisms of negative-feedback signaling, the relative potency of platelet agonists, and cell-to-cell
variation across platelet populations.

1.4.3

Novel Methods for Construction and Analysis of Signal Transduction Models

The formidable size and complexity of these two kinetic models prompted us to devise a new strategy for constructing large-scale kinetic networks. This method, described in Chapter 5, involves
building the model in stepwise fashion, beginning with small “resting” subnetworks that are combined to form larger networks with complex time-dependent behaviors. A key step in the method
is the enforcement of a “homeostasis requirement” on all subnetworks, which ensures that the concentration for each species does not change with time even though species may undergo a gradual
turnover through coupled reactions. Interestingly, we found that only a minor fraction of potential
model conﬁgurations were compatible with resting behavior in an example signaling system. These
reduced sets of conﬁgurations were used to limit the search for more complicated solutions that
also captured the dynamic behavior of the system. Using an example model constructed by this
approach, we show how a cell’s resting behavior adjusts to changes in the kinetic rate processes
of the system. This strategy oﬀers a general and biologically intuitive framework for building
large-scale kinetic models of steady-state cellular systems and their dynamics. The ﬁnal chapter
summarizes the main ﬁndings and implications of our systems analysis and proposes a new method
for constructing and analyzing models of cellular signaling using artiﬁcial neural networks.
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Chapter 2

Phosphotyrosine Signaling in the
Epidermal Growth Factor
Receptor
The Erb family of receptors—the epidermal growth factor receptor (EGFR or ErbB1 or HER1),
ErbB2 (or HER2), ErbB3, and ErbB4—activates a multi-layered network mediating crucial pathways leading to cell proliferation, diﬀerentiation, migration and altered metabolism [33,67,141,180]
in response to activation of the receptor by the epidermal growth factor (EGF), transforming growth
factor-a (TGF-a), and several other related peptide growth factors [33]. Erb family of receptors
are receptor tyrosine kinases (RTKs); RTKs are transmembrane glycoproteins with a cysteine rich
ligand-binding extracellular domain, a transmembrane domain important in dimerization, and an
intracellular tyrosine kinase domain with a tyrosine rich C-terminal tail [67, 141]. Activation of
the ligand-binding domain by an extracellular ligand leads to homodimerization or heterodimerization among the members of the Erb family. The process of ligand-induced dimerization is now
quite well understood, based on crystallographic studies [22, 54]. Precisely how this ligand-induced
dimerization event is coupled to, and leads to, activation of the intracellular tyrosine kinase domain
has also emerged from recent crystallographic studies [184]. The crystal structure of the EGFRTK
domain was ﬁrst published in 2002, both alone and in complex with an inhibitor erlotinib [159], and
displayed several unique features. While structural studies of the kinase domains from other RTKs
(and protein kinases in general) have shown them to be catalytically inactive until an activation
event such as ligand-induced dimerization causes them to become autophosphorylated within the
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activation loop [67] and subsequently become locked into a characteristic active conformation [115],
members of the EGFR family appear to be unique in not requiring activation loop phosphorylation
for their activity [60]. The crystal structure of an unphosphorylated form of the EGFR kinase
domain was found to be constitutively locked in the active conﬁguration [159]. In a recent pioneering crystallographic study, it is suggested that the kinase domain of the EGFR is regulated
by a direct allosteric stabilization of the active conformation [184]: speciﬁcally, the kinase–kinase
contact through an asymmetric dimer interface allosterically promotes the active conformation.
Indeed, such an interface is inferred from (and experimentally realized by) the presence of a high
concentration of the kinase domain in the crystals. The study also reported a crystal structure
of the V924R mutant of EGFRTK in an inactive form which aligned closely with a previously
solved structure of wildtype EGFRTK bound to the inhibitor lapatinib [179]. The mutation replaces a hydrophobic residue at the dimer interface with a charged group thereby destabilizing
the dimer interface. As a consequence, the EGFRTK domain retains its inactive state and relaxes
into an alternative crystallographic lattice which does not support the activating asymmetric dimer
interface.
It is well established that alteration or overexpression of EGFR and ErbB2—two (of four) members
of the ErbB family of RTKs—is correlated with a variety of clinical cancers [109,149]. Hence, small
molecule RTK inhibitors for EGFRTK and ErbB2 RTK are also of signiﬁcant interest as cancer
therapeutic drugs. Small molecule tyrosine kinase inhibitors (e.g., anilinoquinazoline compounds
such as geﬁtinib and erlotinib), which are ATP analogues [5, 6, 75, 113, 133], have been shown
to exhibit growth inhibitory eﬀects against a wide variety of human tumors [28–32]. The RTK
inhibition approach has shown promise in some clinical trials, but results have been quite mixed
[40]. In particular, despite the promise in a small demographic sub-population with signiﬁcantly
advanced disease, clinical responses to geﬁtinib and erlotinib varied among population samples.
Recently, somatic mutations L834R, L837Q, G685S, del L723-P729 ins S 1 in the EGFRTK domain
were reported to correlate with the clinical response of geﬁtinib and erlotinib [23, 89, 106, 120].
In vitro, these EGFR mutants demonstrated enhanced tyrosine kinase activity in comparison to
wildtype EGFR and increased sensitivity to inhibition [6, 27, 41, 42, 106, 120, 121, 157]
Although the underlying biochemical basis for the observed drug sensitivity of the mutations is still
not clear, the remarkable sensitivity of cell lines carrying geﬁtinib-sensitizing mutants appears not to
be centered around inhibitor or ATP binding aﬃnities, but rather on other biochemical mechanisms
regulating the EGFRTK activity and EGF-mediated signaling [48]. In a recent review, the ErbB
signaling network is likened to a bow-tie-conﬁgured, evolvable network, displaying modularity,
1 there is an alternate clinical numbering scheme used in the literature with an oﬀset of 24 residues according to
which these mutations are denoted by L858R, L861Q, G719S, del L747-P753 ins S
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Kinetic Monte Carlo
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Signal transduction
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Figure 2.1: Scheme for hierarchical multiscale simulations.
redundancy, and control circuitry [33]. Under this framework, identifying the role and signiﬁcance
of drug sensitizing mutations of ErbB receptors would require a systems-level understanding of
the signaling network [71–73] This would prove to be of enormous value in eﬀectively designing
multikinase inhibitors for the development of cancer therapies that target several points along the
signaling pathway simultaneously [48, 77]. Evidence emerging from biochemical studies points to
diﬀerential phosphorylation rates associated with diﬀerent tyrosine phosphorylation sites in the
receptor [1, 80, 157, 178]. Moreover, recent structural studies have indicated that the clinically
identiﬁed mutations are able to alter regulatory elements within the receptor so as to bypass the
dimer-mediated activation step and lead to constitutive activity. Therefore, understanding the
eﬀect of such mutations on preferential signaling can be crucial in shaping the signaling response
in cell lines derived from cancer patients.
In this chapter, we adopt a multiscale modeling approach (see Figure 2.1 and Table 2.1) to study
the dimer-mediated receptor activation characteristics of EGFRTK. Through these modeling approaches, we are able to extend the prior modeling of EGF-mediated signal transduction by considering speciﬁc EGFRTK docking interactions mediated by diﬀerential binding and phosphorylation
of diﬀerent C-terminal peptide tyrosines on the RTK tail. By modeling signal ﬂows through branching pathways of the EGFRTK resolved on a molecular basis, we are able to transcribe the eﬀects
of molecular alterations in the receptor (e.g., mutant forms of the receptor) to diﬀering kinetic
behavior and downstream signaling response.
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Method
Molecular
dynamics
(MD) simulations

Free energy docking

Generalized Langevin
dynamics,
kinetic
Monte Carlo

Transient system dynamics

Scale
Å-nm, fs-ns

Å-nm, fs-ns

nm-m, μ s-s

μ m, ms-s

Elastic
Properties
of membranes, persistence length of
disordered
protein
chains
Initial expression levels, rate laws, kinetic
parameters

Protein
conformations
from
MD
simulation

Input
Structure, force-ﬁeld,
system parameters

Time course proﬁles,
signal ﬂow, sensitivity analysis

Output
Trajectory, hydrogenbond tables, dominant motion, free energy
Binding modes, binding aﬃnities for inhibitor, ATP, peptide
substrates
Time scale for Cterminal substrate tyrosine binding and for
internalization

Table 2.1: Summary of multiscale simulations.

Signal transduction

Protein intramolecular
large-scale motion, proteinmembrane interaction

Proteinligand interaction

Biological scope
Protein structure simulation

Pharmacological
mutant systems

studies,

Micropipette, confocal microscopy, dielectric relaxation

Crystal structure; KM , KI
values from aﬃnity studies

Experimental validation
Crystal structure, mutation studies

2.1
2.1.1

Summary of Methods
Molecular Dynamics (MD)

Dynamics trajectories of fully atomistic, explicitly solvated systems of wildtype and L834R mutant
EGFRTK are obtained and analyzed for speciﬁc stabilizing interactions such as hydrogen bonds
and salt-bridges.

2.1.2

Molecular Docking

Molecular docking is used to predict ligand binding in the absence of a ligand-bound crystal structure and functional aﬃnity data. We employ AutoDock, an automated docking tool designed to
predict how small molecules, such as substrates or drug candidates, bind to a receptor of known
3-dimensional structure [112]. The binding free energy is calculated based on the intermolecular
energy between protein and ligands and torsional and solvation free energy of the ligands [112]. We
perform a global conformational search using a multiple conformation docking strategy, in which
the protein ﬂexibility is taken into account implicitly.

2.1.3

Signal Transduction

EGF stimulation in a cell results in the simultaneous activation of multiple pathways that are
functionally interlinked [80,141,142]. In the kinetic model we have employed, signaling through the
EGFR is modeled by combining three published models and augmented by our own set of reactions
and calculations. Phosphorylation and docking reactions are modeled according to Kholodenko
et al. [86]; the MAP kinase pathway reactions are modeled after Schoeberl et al. [147]; Akt and
PI3K activation are incorporated into the model as described in Brown et al. [21]. The similar
parameterization and topology in these models allowed us to construct a consistent, stable, and
comprehensive system with results in good agreement with published experimental data [140].
Seventeen of these reactions are novel to this work and represent enhanced molecular resolution
and detail in EGFR activation, phosphorylation, and docking reactions (2.2 and 2.2). Using the
system model, we calculate the state levels of well-known downstream indicators of cell growth and
proliferation, such as phosphorylated ERK and Akt. Each output state is quantiﬁed according to
peak response, total (integrated) state level, and the time elapsed until peak response.
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Figure 2.2: Phosphorylation model for EGFR. (v1) EGF binds reversibly to EGFR, which increases the receptors aﬃnity for other ligand-bound receptors (v2). Basal levels of spontaneous
dimerization also occur (v3, v4; not shown). ATP binds reversibly to the catalytic site of the
receptor (v5). The transient ATP-bound EGFR must then encounter a free unphosphorylated
peptide on either cytoplasmic tail in a diﬀusion-limited step (v8v11). (v12) The receptor catalyzes
autophosphorylation at either Y1068 or Y1173 (for clarity, only the Y1068 site is shown). Reactions
with an asterisk denote more than one reaction involving similar kinetics but diﬀering substrates
(see 2.2).
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Mechanism
[EGFR] + [EGF] 
 [EGFR:EGF]
[EGFR:EGF] + [EGFR:EGF] 
 [EGFR2 ]
[EGFR] + [EGFR] 
 [EGFR2 ]
[EGFR2 ] + [ATP] 
 [EGFR2 :ATP]
[EGFR2 :ATP] 
 [EGFR2 :ATP:Y1068]
[EGFR2 :ATP] 
 [EGFR2 :ATP:Y1173]
- P
]
[EGFR2 :ATP:Y1068] → [EGFRY1068
2
Y1173 - P
]
[EGFR2 :ATP:Y1173] → [EGFR2
- P
]
→
[EGFR
]
[EGFRY1068
2
2

Parameter values
kf = 310−7 M −1 s−1
kf = 110−7 M −1 s−1
kf = 310−7 M −1 s−1
Km = 2.410−8 M −1
kf = 6.51105 s−1
kf = 1.98105 s−1
kc at = 0.29s−1
kc at = 0.25s−1
Vmax = 4.510−7 M −1 s−1

Km = 5.010−8 M −1

kr = 769s−1
kr = 48.1s−1

kr = 3.810−3 s−1
kr = 0.1s−1
kr = 3.810−3 s−1

Reference
[86]
[86]
[86]
[19]
[51]
[51]
[51]
[51]
[86]

Table 2.2: Reaction mechanisms and parameterization for EGFR phosphorylation reactions. a An identical rate equation was employed for
spontaneous dimerization of EGFR and EGFR:EGF (v4).

Reaction
v1
v2
v3a
v5
v8
v10
v12
v14
v16

2.1.4

Intramolecular Diﬀusional Timescales of C-terminal Tail Tyrosines
in Auto- and Trans-phosphorylation

Auto- as well as trans-phosphorylation of speciﬁc tyrosine sites in the C-terminal tail of the receptor
involves diﬀusion of the particular tyrosine residue in the C-terminal tail to the active site of
the EGFRTK. We model the tail diﬀusion as a freely joined chain (FJC) consisting of Kuhn
segments [44]. The diﬀusion coeﬃcient of the tyrosine residue is then calculated using a reptation
model [44]. The reciprocal of the diﬀusional time of a speciﬁed tyrosine residue to reach the active
site is taken as the kon for substrate binding.

2.1.5

Spatial Stochastic Model for Endocytotic Vesicle Nucleation

Clathrin mediated endocytosis is a major mechanism for the down regulation of activated receptor
proteins. The assembly of a clathrin coat proceeds via a polymerization of clathrin trimers [143],
which is observed to coat the endocytotic vesicle. However, it is believed that the clathrin coat
alone may not be capable of inducing the required curvature in the membrane. Another protein,
epsin, in fact plays a crucial role in inducing the curvature of the membrane [52, 56]. The protein epsin has binding sites in the clathrin lattice and also directly interacts with the membrane.
This dual interaction together with the dual interaction of an adaptor protein Ap180 with clathrin
and the membrane (Ap180 tethers the clathrin coat to the membrane) is believed to induce the
vesicle nucleation and anchor the clathrin lattice to the budding vesicle. Recently, we developed
the KMC-TDGL (kinetic Monte Carlo- time-dependent Ginzburg Landau) heterogeneous multiscale
approach for studying membrane dynamical processes by combining two diﬀerent phenomenological
theories [172]. Simulations performed using this approach yields the time evolution of the membrane undulations and deformation in response to the diﬀusion of membrane bound epsins and a
timescale for the nucleation of an endocytotic vesicle. We calculate the timescale for epsin-induced
endocytotic vesicle nucleation from our membrane simulations performed using the KMC-TDGL
approach [172]. We combine this timescale for nucleation with the timescales for signal transduction calculated using the network simulations to estimate an overall timescale for phosphorylated
receptor internalization.
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2.2
2.2.1

Results
Dimer Mediated Activation of EGFRTK

We performed two 10 ns molecular dynamics (MD) simulations of the EGFRTK system in the active and the inactive conformations, respectively. Based on a comparison of the crystal structures–
active: erlotinib-bound, wildtype [159], AMP-bound wildtype [184]; inactive: lapatinib-bound wildtype [179], V924R mutant [184]–we conclude that the conformational switching from an inactive
to an active conformation involves a rotation of the α C-helix of EGFRTK and the shifting of the
activation loop (A-loop) residues to make way for peptide and ATP binding. The recent study of
Zhang et al. [184] has implicated a dimer-mediated activation mechanism for the EGFRTK. That is,
loss of interactions upon RTK dimerization leads to switching of the conformational state of the enzyme from inactive to active conformations. On this basis, we hypothesize that speciﬁc interactions
(namely, H-bonds and salt-bridges) between the residues of the α C-helix and those of the A-loop
need to reorganize in the course of the conformational switching from inactive to active states. To
elucidate the nature of these interactions, a hydrogen bond analysis focusing on the residues surrounding the A-loop, α C-helix, catalytic loop, and nucleotide-binding loop was carried out using
CHARMM6 and VMD30 programs. The MD trajectories were ﬁrst analyzed in CHARMM with a
hydrogen bond cutoﬀ of 2.4 Åand a cutoﬀ angle of 150◦ . We generated a list of hydrogen bonds
that were present in at least 60% of the trajectory. These hydrogen bonds were then visualized in
VMD and any non-signiﬁcant bonds were removed to reveal the stabilizing H-bonds. During the
H-bond analysis, acidic and basic residues formed strong hydrogen bonds, similar to salt-bridges.
The A-loop and α C-helix conformations were stabilized by internal hydrogen bonds (i.e., both the
residues participating in the hydrogen bond are within the loop/helix), as well as external hydrogen
bonds (i.e., one residue is in the loop/helix, the other is not). The residues participating in these
stabilizing interactions are predominantly acidic and basic residues. A comparison of the speciﬁc
interactions showed that the number of external interactions stabilizing the A-loop and α C-helix
in the active conformations far out-numbered those in the inactive conformations (Figure 2.3 and
Table 3 of ref. [102]). Intriguingly, the small number of stabilizing interactions holding the kinase
in the inactive are predominantly located proximal to the dimer-interface residues (Table 3), which
lends further credibility to the allosteric activation mechanism [184] of the wildtype. Namely, that
loss of dimer-interface residues will alter the surrounding stabilizing bond network, leading to the
destabilization of the inactive conformation and triggering the conformational shift to the active
conformation.
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Figure 2.3: Visualization of the stabilizing residues external to A-loop and α C-helix (shown in
blue), dimer interface residues (shown in red), and clinical mutations (shown in green) of both the
active (panel a) and inactive (panel b) EGFR tyrosine kinases. The A-loop is highlighted in sky blue
while the α C-helix is shown in purple, the remainder of the protein is colored orange. The external
stabilizing residues for the EGFR tyrosine kinases are numbered from 140, with 127 corresponding
to residues in the active state while 2840 correspond to the stabilizing residues in the inactive state.
The stabilizing residues that are potentially aﬀected by dimerization are highlighted in red boxes,
and the residues that are potentially aﬀected by the clinical mutations are highlighted in green boxes
(See also Table 3 of ref. [102]). The inactive conformation has fewer stabilizing bonds holding the
conformation stable: 13 stabilizing residues as opposed to 27 stabilizing residues. Therefore, the
loss of interactions triggered by either mutation or dimerization will have a greater eﬀect upon the
stability of the inactive kinase and allow a conformation change. The numbered labels correspond
to the residue numbers as follows: 1:672 2:679 3:721 4:728 5:732 6:734 7:737 8:738 9:740 10:741
11:743 12:744 13:745 14:808 15:810 16:812 17:832 18:834 19:836 20:838 21:840 22:843 23:845 24:848
25:851 26:867 27:932 28:738 29:740 30:742 31:744 32:753 33:812 34:813 35:834 36:836 37:846 38:848
39:851 40:865.

2.2.2

Constitutive Activation of the L834R Mutant

The clinically relevant mutations del724-729 and L834R are located in distinct parts of the enzyme
but both mutations lead to enhanced receptor activity [25, 106, 120, 157]. Our delineated pattern
of stabilizing interactions in Table 3 in ref. [102] serves as a platform for unifying the eﬀects
of these mutations at a structural level. The small number of stabilizing interactions holding
the kinase in the inactive conformation also overlaps with the residues associated with several
clinically relevant mutations. The deletion mutant interferes directly with the dimer interface, and
both the R substitution of L at 834 as well as R substitution of Q in 837 destabilize the speciﬁc
(external H bonds) interactions associated with A-loop and α C-helix in the inactive but not the
active conformation. Thus, these mutations have a deleterious eﬀect (see Table 3 of ref. [102])
in stabilizing A-loop and α C-helix conformations in the inactive state—hence, they stabilize the
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active conformation. Indeed, in one of our MD trajectories initiated from the active conformation
of the wildtype monomer RTK, we observed the motion of the enzyme towards the inactive state
in 10 ns. In this case, a key interaction between two residues in the α C-helix and the A-loop (saltbridge between GLU851 and LYS734, see also Table 3 of ref. [102]) was broken. In stark contrast,
a 12 ns MD trajectory of the L834R mutant system (under similar conditions) remained stable in
the active conformation. The collective evidence from these observations points to a constitutively
active L834R mutant RTK system (i.e., activated in monomer and dimer states in the presence or
in the absence of an EGF ligand) and a dimer-mediated activation of wildtype RTK (i.e., activated
only in the dimer state in the presence of the EGF ligand).
Experimental observation of constitutive activation in the geﬁtinib-sensitive EGFR mutants has
been recorded independently in several studies, which report signiﬁcantly elevated basal phosphorylation (in the absence of the stimulating ligand) of the mutant systems in comparison to the
wildtype [25, 26, 120, 157]

2.2.3

Ligand and Substrate Binding Aﬃnities for EGFRTK

We determine the ATP and erlotinib binding modes and binding aﬃnities based on our multiple
conformations docking strategy and analyze several low-energy clusters of ligand conformations.
For both wildtype and L834R mutant EGFRTK systems, one lead erlotinib binding conformation
is found to be closely aligned with that in the crystal structure: the hydrogen bonds between the
N1 of the quinazoline and Met769 are present and so is the interaction between Thr766 and the
quinazoline nitrogen atom (N3). The binding modes for ATP and erlotinib are also consistent
with the existing pharmacophore model for ATP binding to kinases [164, 165, 183]. Signiﬁcantly, a
second binding mode, which has a higher aﬃnity to the mutant kinase L834R, is revealed in our
calculations. This mode still blocks the ATP binding pocket and in addition shows an additional
interaction between erloitnib and the R834 residue. The eﬀect is a higher calculated binding aﬃnity
for erlotinib binding to L834R (-9.4 0.4 kcal/mol) in comparison to wildtype (-7.3 0.5 kcal/mol).
In order to explore the C-terminal peptide-substrate-bound pre-catalytic conformation, we also
dock EGFRTK substrate peptides to the catalytic site. First, we focus on an optimal peptide
sequence EEEYFEL as a control. This optimal sequence is selected for a maximal value in kcat /KM
among EGFRTK substrate peptides [156]. Based on 5001000 diﬀerent genetic algorithm runs
for docking of this peptide to EGFRTK, we select the best binding conformation for binding as
one that yields the lowest binding free energy simultaneously with the correct orientation for the
tyrosine binding into the active site. The latter criterion is essential in ensuring that kcat is not
signiﬁcantly compromised in obtaining a stronger binding. We depict in Figure 2.4 the peptide
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conformation bound to the active site, which is seen to be ideally poised for a two-metal-ion
catalyzed phosphoryl transfer from ATP to the bound tyrosine [110,160]: i.e., the relative positions
of the ATP, Mg2+ ions, and the catalytic aspartates are in good alignment. Encouraged by this
result, we performed peptide docking simulations for two substrate peptides (each being seven
amino acids long) corresponding to the Y1068 (VPEYINQ) and Y1173 (NAEYLRV) sites of the Cterminal tail for both wildtype and L834R mutant structures. Based on a similar criteria of lower
binding free energy and optimal catalytic geometry, we calculated the peptide binding aﬃnity
corresponding to sites Y1068 and Y1173 for wildtype and L834R mutant systems. Upon mutation,
the calculated KM for the Y1068 peptide decreased 20-fold (calculated ΔΔG [wildtype → L834R]
= −2.2 kcal/mol), while the calculated KM for the Y1173 peptide increased 4-fold (calculated ΔΔG
[wildtype → L834R] = +0.9 kcal/mol). Analysis of the binding modes reveals that the relative
alignment of the tyrosine with respect to the catalytic site is ideal (2.2 Åin the observed distance ξ
between Tyr OH oxygen and Asp 813 Oδ2 ) for the two peptide tyrosines binding to wildtype, with
the two mutant systems showing a 01.5 Ådeviation. The diﬀerences can translate into diﬀerences
in kc at values associated with the tyrosine phosphorylation. Assuming a harmonic energy proﬁle
along the reaction coordinate ξ with a force constant Kξ , the work done in reducing this distance
is given by 1/2Kξ ξ 2 . The value of Kξ is obtained by recording the ﬂuctuations of ξ in the MD
2
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simulations (Kξ = kB T /σξ 2 = 0.77kcal/mol/Å for the wildtype and 1.01kcal/mol/Å for L834R),
where σξ is the standard deviation associated with the ﬂuctuations in ξ in the trajectories). The
normalized values of kcat /KM can then be compared for the four systems at the same value of
Y 1068
ξ = 2.2Å); the relative increase in kcat /KM
for the L834R in comparison to the wildtype is 20-

fold (increase by 1-order of magnitude), while the relative decrease for Y1073 is 200-fold (decrease
by 2-orders of magnitude). This diﬀerential sensitivity translates into diﬀerences in phosphorylation
of the associated tyrosine sites, which ultimately leads to diﬀerential signaling and down stream
activation in the EGFR network: the Y1173-phosphorylation is associated Shc mediated ERK
activation and Y1068 phosphorylation is associated with Akt activation [80, 157].

2.2.4

Timescales Associated with Diﬀusion of Substrate Tyrosines Binding Prior to Auto- and Trans-phosphorylation and with Endocytotic Vesicle Nucleation

C-terminal Tail Diﬀusion
We calculate the diﬀusional time scale for each of the seven tyrosine residues present on the Cterminal tail of EGFRTK to reach the active site Table 2.3. The timescales for diﬀusion are in μ s
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Figure 2.4: Binding modes for ATP (cyan) and the optimal peptide sequence (yellow) in the
EGFRTK domain. The geometry of the active site is consistent with that prescribed for an ideal
two-metal-ion catalyzed mechanism and reveals a state that is poised for the phosphoryl transfer
reaction. The alignment of the two divalent Mg2+ ions as well as the catalytic aspartates D813 and
D831 are also shown.

and are fairly similar for the diﬀerent tyrosine sites to bind to the active site prior to auto- (head)
or trans- (tail) phosphorylation. For each case, the reciprocal of the corresponding timescale is
taken as the on-rate (kon ) of the tyrosine binding to the active site. The oﬀ-rate is calculated as
kof f = kon × exp(+ΔG/kB T ), where ΔG is the binding free energy of the substrate to the active
site; here it is assumed that the binding process is diﬀusion-limited with no signiﬁcant additional
barriers. The values for ΔG for each C-terminal tyrosine is obtained from the analogous data
on peptide substrate aﬃnities KM published in the literature [19, 51]: kΔG/kB T = −ln(KM ).
These calculated values are used in the model for signal transduction described in Section 2.1.3 and
provided in Table 2.2.
Endocytotic Vesicle Nucleation
In our earlier work, we identiﬁed diﬀerent regimes conducive to nucleation of an endocytotic vesicle
by exploring a range of parameters associated with the membrane adsorbed proteins, such as surface
density of the protein on the membrane, and the intrinsic curvature of the membrane induced by the
proteinmembrane interaction [172]. Here, we report our results speciﬁcally for epsins interacting
with the membrane. Consistent with the experimental values of Ford et al., we assume that the
intrinsic membrane curvature induced by the epsin molecules falls in the range of 10μm−1 . We
further assume that the distance from a given epsin molecule that this curvature eﬀect decays
21

Tyrosine residue

Y992
Y1045
Y1068
Y1086
Y1101
Y1148
Y1173

Diﬀusional time to the active site (μs)
Head
Tail EGFRTK (trans-phosphorylation)
EGFRTK
(autophosphorylation)
0.34
0.65
1.72
2.54
2.64
3.68
3.49
4.7
4.26
5.61
7.26
9.08
9.16
11.22

Table 2.3: Diﬀusional time for C-terminal tyrosines to reach the active site of EGFRTK.

is four times the epsin diameter. A depiction of our ﬁndings for an epsin surface density (on
the membrane) of 60 per μm2 is given in Figure 2.5, in which in the time course of 250400 s,
the nucleation of a vesicle is observed (see snapshots in panels BD). Panels E and F provide the
corresponding spatial and orientational correlations [172]. The necessary condition for nucleation
is the persistence of orientational (hexagonal) ordering of the membrane-adsorbed epsin molecules
(see caption) [172]. Our results have suggested an interesting mechanism for the epsin-mediated
membrane invagination. Namely, the invagination occurs through a nucleation event, which involves
the colocalization and hexagonal ordering of several epsin molecules on the membrane. Based on
our results (Figure 2.5), the timescale for nucleation of such an event is 250400 s.
As described in Section 2.1.3, receptor activation, which is eventually followed by receptor internalization (via endocytosis), results in triggering many signal transduction cascades—one of which is
the PLC-β pathway [13,180]. The PLC-β pathway is accompanied by a transient release of calcium
ions from intracellular stores. Models for the transient release of calcium have been developed on
the basis of several published experimental studies [90, 154]. We work under the hypothesis that
the signal transduction in the endocytosis pathway is coupled to membrane deformation via two
functional interactions: (1) the direct induction of curvature via the interaction of the membrane
lipids with epsin [52, 123, 144, 158]; and (2) through the assembly of the clathrin coat [144, 181],
which is triggered by an increase in the local concentration of Ca2+ ions released in the PLC-β pathway [13]. In the latter case, above a threshold value of Ca2+ concentration the clathrin monomers
spontaneously self-assemble to form a lattice [144, 181]. This leads to the following mechanism for
endocytosis. The transient increase in calcium concentration at the site of the activated receptor helps promote clathrin polymerization and coat assembly. The adapter protein Ap180 tethers
the clathrin lattice on the membrane. The vertices of the hexagonal lattice of the clathrin coat
provide binding sites for epsins. Thus, in the vicinity of the activated receptor, the membrane
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Figure 2.5: (a) Depiction of the system of epsin molecules interacting with the membrane.
(bd) Snapshots of the system at diﬀerent time points (the epsin positions are not shown for clarity). The blue regions are recessed and red regions are elevated in the membrane. The nucleation
of a budding vesicle in the membrane is evident in panel d. (c) Spatial correlation function for
the membrane adsorbed epsins. (f ) Orientational correlation function for the membrane adsorbed
epsins. The correlation functions are provided for 3 simulation runs at diﬀerent epsin densities
(ρ∗, dimensionless) and values of the induced curvature (c0 expressed in μm−1 ). The value of a
dimensionless density (ρ∗ = 0.024 corresponds to 60 epsins per μm2 . The snapshots correspond to
the red symbols in panels e and f (ρ∗ = 0.024 and c0 = 10μm−1 ). For this case, there is persistence
of orientational correlations (hexagonal ordering), see panel f. For the other two cases in panels e
and f (for which snapshots are not shown), no nucleation and no signiﬁcant orientational ordering
is observed.

adsorbed epsins assume a spatial conformation with persistent orientational correlations induced
by the clathrin lattice. This provides the condition for a nucleation event leading to formation of
the endocytotic vesicle. (We note that according to this mechanism, unactivated receptors can also
internalize; however, in the absence of the transient calcium surge, which only occurs upon receptor
activation, the clathrin coat assembly may represent a slower step).
An estimate for the timescale of receptor internalization τ (internalization) is therefore obtained by
the sum of timescales for receptor phosphorylation at Y1045, PLC-β activation, calcium release,
clathrin coat assembly, and nucleation of epsin-mediated vesicle formation.

2.2.5

Diﬀerential Signaling through EGFRTK

By employing the deterministic model described in Section 2.1.3 (see Figure 2.2 and Table 2)
we have calculated transient evolution of the EGF-mediated signaling network under a variety of
initial conditions and parameter values. In particular, we have focused on two pools of normal
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Figure 2.6: Calculated ERK and Akt phosphorylation levels in units of nM (peak levels over the
time course of 1000 s) under serum starved (EGF-) and serum cultured (EGF+) conditions for cell
types with normal EGFR expression and EGFR overexpression. In each panel the Y1173 rate of
phosphorylation (kcat /KM ) is varied along the x-axis (value relative to wildtype EGFRTK) and
the Y1068 rate of phosphorylation (kcat /KM ) is varied along the y-axis. In each panel, the blue
circle denotes the wildtype levels and the green square denotes those relevant to the L834R mutant
cell lines.

([EGFR] = 100 nM or 33,000 receptors per cell) and overexpressed ([EGFR] = 2000 nM or 660,000
receptors per cell) EGFR concentrations, each in the absence (serum starved, [EGF] = 0 nM) and
presence (serum cultured, [EGF] = 8 nM) of the EGF ligand. Since our molecularly resolved model
(Figure 2.2) is currently focused on diﬀerential signaling through Y1068 and Y1173 phosphorylation
sites of EGFRTK, we track the integrated response of ERK and Akt phosphorylation levels in our
simulations. Each output state was quantiﬁed according to the peak level of phosphorylation over
the simulated time of 1000 s. Speciﬁcally, we perform a two-dimensional scan over kcat /KM values
associated with Y1068 and Y1173 phosphorylation in which the respective kcat /KM values are
allowed to deviate from their default (wild-type) value over a logarithmic range of ﬁve log units.
The result is a two-dimensional matrix in which each element represents output from a single
simulation involving a unique pair of parameters (Figure 2.6).
The simulated response of the EGFR network also enables us to estimate a timescale for receptor
internalization τ (internalization). The typical timescale for EGFRTK phosphorylation is in the
range of 10 s, while that for PLC-β activation is 50 s. The calcium release from intracellular stores
through the activation of IP3 R (IP3 receptors) is reported to occur within a short timescale of
10 s [154]. While the timescale for clathrin coat self-assembly under high calcium concentration
is not known, it is assumed here that this is a rapid process. According to our results from the
spatial stochastic simulations (Section 2.2.4), the epsin mediated endocytotic vesicle nucleation in
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the presence of the clathrin coat is calculated to occur in a timescale 250400 s. Further, assuming
that the stabilization of the budding endocytotic vesicle and the vesicle pinch-oﬀ process catalyzed
by dynamin are not rate-limiting, the estimated time for vesicle internalization upon EGF ligand
binding is ≈450 s (≈8 min). We note that these timescales from our simulations are ball park
estimates and we have not yet attempted a careful comparison with timescales from experimental
measurements.

2.3

Discussion and Conclusions

Based on an integration of a large body of knowledge accumulated over the years, the modular nature of EGFR-mediated signaling has become apparent [33, 71]. Through a hierarchical multiscale
modeling scheme, we have realized a molecular resolution to this system-level view that can potentially augment our predictive as well as comprehensive capabilities and rationalize the changes in
early signaling characteristics of altered and mutant cell lines. Our overall ﬁndings are summarized
below.
Analysis of stabilizing interactions in our molecular dynamics simulations have corroborated a
dimer-mediated activation mechanism for the EGFRTK. That is, loss of key stabilizing interactions
in the inactive conformation of the kinase upon dimerization results in destabilizing the inactive
state and triggering a conformational change to the active state. Moreover, our results point
to a constitutively active L834R mutant. That is, even in a monomer state, the RTK of the
L834R mutant system is stabilized in an active conformation and can trigger signaling through
the EGFR network by auto-phosphorylation of its C-terminal tail tyrosine residues in an EGF
(ligand) independent manner. These results are consistent with the existing biochemical data
[25, 106, 120, 157, 184] that have qualitatively shown that the phosphorylation of C-terminal tail
tyrosines of the L834R mutant in the absence of EGF stimulation is comparable to wildtype values
in the presence of EGF stimulation at EGF concentrations of 30100 ng/ml.
Our results from the free energy docking simulations suggest enhanced binding of the inhibitor
erlotinib to the L834R mutant system in comparison to wildtype binding. Our results also reveal
preferential binding and phosphorylation of certain C-terminal tyrosine substrates (but not others)
to the L834R mutant in comparison to the wildtype: that is, the calculated change in the turn over
rate (kcat /KM ) upon the L834R mutation is markedly diﬀerent for the Y1173 peptide in comparison
to the Y1068 peptide. This results in a diﬀerential sensitivity at the receptor level. Speciﬁcally, the
estimated increase in kcat //KM for the Y1068 peptide is ≈10-fold in comparison to a decrease of
1̃00-fold for the Y1173 peptide. Thus, we expect to see a net increase in phosphorylation of Y1068
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and a net decrease in phosphorylation of Y1173 for the L834R mutant, in comparison to wild-type
levels. The biochemical results of Sordella et al. [157] and Chen et al. [25] corroborate this view
qualitatively; in these studies, the immunoblots measuring the degree of phosphorylated receptor
at the Y1173 site show a modest decrease for the L834R mutant in contrast to a strong increase
for the Y1068 site, both in comparison to their respective wild-type measurements.
Our systems level simulation illustrates how the altered aﬃnities at the receptor level for the
wildtype and L834R translates into changes in the downstream response. In Figure 2.6, we explored
how the variation in Y1173 and Y1068 phosphorylation aﬀects the peak responses of ERK and
Akt for two diﬀerent EGFR concentrations, each in the absence or presence of EGF stimulation.
The calculated responses for the wildtype values are highlighted by the blue circles at the origin
of each of the panels. The responses for L834R are identiﬁed by the green square centered at
a (kcat /KM )/(kcat /KM )wildtype value of 1/100 (−2 in log10 units) for Y1073 and 10 (+1 in log10
units) for Y1068. Owing to the constitutively active characteristic of the L834R mutant, the signals
relevant for the L834R system (even in the absence of EGF) are analogous to those in the panels
with EGF stimulation. As indicated by the color maps in these two scans, increasing the degree
of phosphorylation of the Y1173 site (positive x-direction) leads to an overall increase in ERK
response. This ﬁnding is consistent with our model which is based on Y1173 being an important
docking site for the Shc and Grb-2 adaptors that lead to Ras activation and subsequent ERK
phosphorylation. For normal EGFR expression, the calculated ERK response in the absence of
EGF is low for the L834R mutant (0.01 nM) but negligible (approximately zero) for the wildtype.
In the presence of EGF the ERK response for L834R is 7-fold lower than that for the wildtype. For
over expressed EGFR, the ERK activation is 7-fold higher in L834R compared to wildtype both
in the presence as well as in the absence of EGF stimulation. Thus, ERK stimulation is higher
in EGFR overexpressed cells. The Akt response relative to the wildtype is 2-fold higher for the
mutant cells under no EGF stimulation and about the same under EGF stimulation for normal
EGFR expression. The Akt response does not seem to be aﬀected by mutation for high EGFR
expression either in the presence or absence of EGF.
Our calculated responses for ERK and Akt signaling for normal EGFR expression agree with the
qualitative experimental observations of Sordella et al. [157] and Tracy et al. [163]: namely, that
the ERK stimulation levels decrease and the Akt levels are maintained for the mutant cells with
normal EGFR expression levels. This preferential activation of Akt in L834R mutant cell lines
observed in these experiments is consistent with the systems level predictions from our simulations.
Moreover, our calculations predict that the preferential Akt activation is not featured in EGFR
overexpressed cells.
26

In light of the overall agreement between simulations and experiment, we can begin to explore
the origins of inhibitor sensitivity in L834R mutant cell lines. The enhanced sensitivity of the
L834R mutant to erlotinib arises from a combination of several eﬀects: (1) the mutant system
has a higher binding aﬃnity to the inhibitor; (2) the constitutive activity of L834R renders the
mutant to be a more potent target for therapeutic inhibition; (3) the diﬀerences in the predicted
downstream response (between the wildtype and the mutant) accounted for by early signaling events
can potentially lead to a divergent long-term behavior in the two systems causing a diﬀerential
sensitivity to inhibition. More conclusive inferences from our modeling results can only be obtained
after we consider the eﬀect of other receptor states (namely, one in which Y845 is phosphorylated)
and interactions with other Erb partners (see below) on down-stream signal response.
In conclusion, we have described the role of a hierarchical multiscale computational approach in
resolving at a molecular level the systems-level model of EGFR-mediated signal transduction, to
help rationalize the collective information emerging from biochemical, cell biology, and clinical
studies. Our approach enables us to transcribe diﬀerences in molecular mechanisms as well as
functional activity originating at the single molecule level into tangible diﬀerences in early signaling
events. Therefore, subject to the well appreciated limitations of computational modeling, this
predictive capability is useful in diﬀerentiating signaling characteristics of mutant cell lines from
the native wild-type case. This molecular-based reﬁnement of the overall EGFR signal transduction
model is a ﬁrst attempt at untangling the diﬀerential nature of early signaling events triggered by
receptor activation and their consequences in shaping the signal transduction in altered cell lines
derived from diﬀerent pathologies. A complete model, which is currently being pursued, will not
only require resolving the diﬀerential characteristics of all of the tyrosine phosphorylation sites in
EGFRTK and their associated substrate recognition properties in EGFR, but also the extension to
other Erb family members in the context of homo- and hetero-dimers. Transactivation of EGFR
occurring through ligand-induced receptor heterodimerization [171] combined with a potential for
diﬀerential signaling adds a palette of ﬁner control elements in the ErbB family signaling network.
Indeed, recent studies have identiﬁed possible mutations in ErbB2 that may correlate with drug
sensitivity in diﬀerent cancers [97,98]. The computational tools described here are ideal for assessing
the likely eﬀect of novel EGFR and ErbB2 mutations and determining whether the drug-sensitizing
mutations implicated in non-small-cell lung cancer also occur in other cancers. We believe that our
model driven approach will in the long-term signiﬁcantly impact the optimization of future small
molecule therapeutic inhibition strategies.
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Chapter 3

Eﬃcacy of Tyrosine Kinase
Inhibitors in Mutants of the
Epidermal Growth Factor
Receptor
In Chapter 2, we employed a hierarchical multiscale computational strategy to study the dimermediated receptor activation characteristics of the Erb family receptors, through which we were
able to transcribe the eﬀects of molecular alterations in the receptor (e.g., mutant forms of the
receptor) to diﬀering kinetic behaviors and downstream signaling responses [102]. Here, we extend
this approach to study the eﬀects of EGFR inhibition through TKIs. By employing molecular
docking in combination with network modeling, we are able to quantify changes in the EC50 of
receptor phosphorylation (i.e. 50% inhibition in the cellular context) and EC50 for the inhibition of
downstream markers (ERK and Akt) upon treatment with the TKI erlotinib, in cell-lines carrying
both wildtype (WT) and mutant forms of the receptor. Based upon our results, we conclude that
the remarkable eﬃcacy of the inhibitor erlotinib in the L834R mutant cell line can be attributed
to a relative gain in eﬃciency over the WT in inhibiting the Akt response.
How such constitutive activation is precisely linked to increased sensitivity to inhibition and the
eﬃcacy of some TKIs remains an interesting question. Recently, Noro et al. [116] reported that the
majority of inhibitor hypersensitive cell lines showed Akt phosphorylation without ligand stimulation while a small fraction of the resistant cell lines displayed this characteristic. On this basis,
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they concluded that Akt phosphorylation without ligand stimulation may play a key signaling role
in TKI hypersensitivity. Sharma et al. [148] proposed the concept of an oncogenic shock, which attributes the hypersensitivity to inhibition in such cancer cell lines to diﬀerential attenuation rates of
pro-survival (triggered by Akt phosphorylation) and pro-apoptotic signals emanating from EGFR
following its inactivation upon inhibitor treatment. Their surmise, like the Noro et al. ﬁnding, is
based on preferential Akt activation, and relies on the assumption that pro-survival signals such
as Akt-(p) dissipate quickly upon oncoprotein inactivation, whereas pro-apoptotic signals linger
suﬃciently long to commit the cell to an apoptotic death. This diﬀerential eﬀect may contribute to
the rapid and dramatic clinical responses observed in some cancer patients treated with selective
TKIs. Hendriks et al. [65] sought to provide a mechanistic basis for enhanced Akt signaling in
geﬁtinib hypersensitive cell lines and suggested on the basis of experimental and computational
results that the geﬁtinib sensitivity is a marker of a reliance on Akt signaling for cell survival that
may be brought about by impaired EGFR internalization in the inhibitor-sensitive cell lines.
Here we describe another possible mechanism that leads to preferential Akt sinaling. Speciﬁcally,
by introducing a molecularly resolved branched network systems model (the molecular resolution
is introduced through a hierarchical multiscale computational strategy to transcribe the eﬀects of
molecular alterations in the receptor, e.g., mutant forms of the receptor, to diﬀering downstream
short-term signaling responses (see Chapter 2)), to study the eﬀects of EGFR signaling and inhibition in WT and mutant cell lines, we are able to quantify: (1) diﬀerences in short-term signaling
in downstream ERK and Akt activation, (2) the changes in the cellular inhibition EC50 associated with receptor phosphorylation (i.e., 50% inhibition of receptor phosphorylation in the cellular
context), and (3) EC50 for the inhibition of activated downstream markers ERK-(p) and Akt-(p),
where (p) denotes phosphorylated, upon treatment with the TKI erlotinib in cell lines carrying
both WT and mutant forms of the receptor. This model also suggests a possible mechanism for
preferential Akt activation in the oncogenic mutants of EGFR implicated in non-small-cell lung
cancer as well as an enhanced eﬃcacy of the inhibitor erlotinib in ablating the Akt response. Using
a simple phenomenological model to describe the eﬀect of Akt activation on cellular decisions, we
discuss how this preferential Akt activation is conducive to cellular oncogene addiction and how
its disruption can lead to the observed hypersensitivity of the inhibitors. We also illustrate that
key network nodes of our model, which were identiﬁed through our sensitivity analysis as those
rendering the network hypersensitive to enhanced ERK-(p) and Akt-(p) levels, have a striking correlation with species implicated in oncogenic transformations in human cancers as well as identiﬁed
in drug resistance mechanisms for the inhibitors geﬁtinib and erlotinib in non-small-cell lung cancer
therapy.
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Parameter
1
AT P
KM
KIerlotinib
Y 1068
KM
Y 1173
KM
Y 1068
kcat
Y 1173
kcat

WT
1
5.0 μM
17.5 nM
265 μM
236 μM
0.29 s-1
0.25 s-1

L834R
1
10.9 μM
6.25 nM
13.3 μM∗
944 μM∗
0.14 s-1 ∗
0.010 ∗

Reference
1
[23]
[23]
[51, 102]
[51, 102]
[23]
[23]

Table 3.1: Parametric diﬀerences between WT and mutant EGFR systems. ∗Calculated from
molecular simulations.

3.1

Methods

Models for the WT and L834R systems each comprised 74 species, 140 parameters, and 77 reactions and are described in detail in Chapter 2. The model parameters are derived from previously
published models [85] and de novo molecular level calculations in our lab [102]. One important difference between the WT and L834R mutant network is that the WT RTK initiates phosphorylation
of C-terminal tail substrate tyrosines only as a dimer, whereas the mutant—owing to constitutive
activation—can initiate phosphorylation as a monomer as well as a dimer [184]. Our molecularly
resolved signal transduction network incorporates diﬀerential signaling through Y1068 and Y1173
phosphorylation sites of the EGFRTK (see Section 3.1.3). To model competitive inhibition by an
ATP analog, we employed the following reactions in our model.
Consistent with our computational studies (our molecular docking studies described in Chapter 2
revealed that the ATP binding aﬃnity of the RTK in the inactive state is 100-fold lower than
that in the active state), the above reactions are implemented as several analogous reactions, such
that an inhibitor molecule may bind to the activated receptor kinase when the substrate tyrosines
are unphosphorylated, or already phosphorylated at either Y1068 or Y1173. To model the kinetic
behavior in the presence of the TKI erlotinib, we used appropriate values for the inhibition constant
(KI ) of erlotinib, binding constant for ATP, and constants for describing the phosphorylation
kinetics of Y1068 and Y1173 peptides for WT and mutant (L834R) receptors. These parameters
are obtained from our molecular-level simulations and from experiments. The parameters are
summarized in Table 3.1.

3.1.1

Systems-level Model Calibration using Genetic Algorithm

Model parameters were reﬁned by calibrating simulation output with data from published cell-base
assays and time-resolved mass spectrometry [185]. A genetic algorithm (GA) was used to identify
parameter sets that produced the closest ﬁts to experimental measurements, using a linear least
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squares distance measure between computed and measured time course data points as the objective
function. Initial estimates of parameters (default values) were taken from published studies, or
computed by molecular docking and stochastic simulations as described previously [102]. In the
GA, each parameter value was sampled from a log-normal distribution (μ = default value, σ = 1
log unit) to allow the parameters (rate constants or initial conditions, except those for [EGFR],
[EGF], and [TKI]) to range continuously over several orders of magnitude but with strong central
tendency for the default value. The GA was implemented with a constant-sized population of 100
parameter sets, mutation rate μ = 0.15, and crossover rate μ = 0.15, for 1000 generations. Fitness
scores for all individuals were evaluated at each generation by computing the objective function.

3.1.2

Model Sensitivity using Principal Component Analysis

In order to obtain a quantitative measure of the sensitivity and robustness of the signaling network
to rate constants and initial concentrations, we employed a Monte Carlo protocol to perturb the
default parameter sets. This was done by generating a random vector of elements ζi from a normal
distribution with mean zero and variance (σ) 0.3, 1.0, and 3.0, then perturbing the default parameters Pi as Pi × exp (ζi ). Network simulations were repeated 2000 times with new (perturbed)
parameter sets and the sets yielding top 500 values for ERK and Akt activation were stored. A
principal component analysis in parameter space (over the 500 stored sets) was carried out in order
to determine the combinations of parameters (i.e., the constitution of the principal eigenvectors),
whose perturbation are likely to render the signaling hyperactive to ERK and Akt phosphorylation,
that is, phosphorylation of ERK/Akt in the perturbed system is greater that in the unperturbed
system. These calculations were performed in two contexts: (1) by choosing the set of rate constants as the parameters Pi , and (2) by choosing the set of initial concentrations as the parameters
Pi .

3.1.3

Diﬀerential Signaling through Y1068 and Y1173

Our molecular resolution to the systems model is enabled by two features in our research design: (1) the de novo estimation of key binding and rate constants associated with the receptor
through molecular simulations, we are able to quantify the molecular contributions to signaling
and hence diﬀerentiate signaling in WT and mutant cells; (2) our systems model introduces the
concept of diﬀerential signaling, where phosphorylation at the Y1068 and Y1173 sites transduces
signals through diﬀerent pathways. This diﬀerential eﬀect was initially incorporated based on experimental evidence [157] by assuming perfect (or 100/0) speciﬁcities for the interactions of the
Y-phosphorylated docking sites: i.e., the phosphorylated Y1068 binds only to PI3K and Grb2 and
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Figure 3.1: Diﬀerential signaling for WT and L834R. Total phosphotyrosine (pY1068 or pY1173)
was calculated after 60 s, with (8 nM) and without ligand (EGF).

not PLC-β and Shc, and phosphorylated Y1173 binds only to PLC-β and Shc and not to PI3K
and Grb2. The alternative approach is to assume no (50/50) speciﬁcity, i.e., the two sites 1068
and 1173, when phosphorylated, serve as docking sites to all four substrates in our model, namely
PI3K, Grb2, PLC-β and Shc. This would reduce to a single-site model, where the docking sites are
not distinguished. A realistic model for incorporating this diﬀerential eﬀect lies between these two
extremes. The degree to which the docking interactions of the phosphotyrosines are speciﬁc can
be determined by molecular docking calculations similar to those described in the section below
(these calculations are ongoing in our laboratory). However, in order to gauge the sensitivity of
the downstream response (ERK vs. Akt activation) on the degree of speciﬁcities, we performed
network simulations with varying degrees of speciﬁcities ranging from 100/0 to 50/50.

3.2
3.2.1

Results and Discussion
Diﬀerential phosphorylation

We ﬁrst assessed the diﬀerential phosphorylation patterns of WT EGFR and L834R mutant systems, with normal receptor copy number (initial [EGFR] = 100 nM or 30,000 receptors per cell),
with 8 nM (50 ng/ml) EGF or without EGF stimulation (Figure 3.1). As expected from the altered
KM and kcat values, L834R has a stronger preference for Y1068 phosphorylation compared to the
WT receptor, while our results predict the opposite trend for Y1173 phosphorylation.

3.2.2

Diﬀerential Signaling

To examine the eﬀects of our branched signaling through pY1068 and pY1173 on the downstream
response, we explored a series of cases in which diﬀerential signaling was fully implemented, i.e.
100/0 (see methods section), partially active (75/25), or completely absent (50/50). In the latter
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case, docking peptides (e.g., PLC-β, PI3K, Gab1) could bind indiscriminately to either phosphorylated tyrosine sites. Simulations were performed for 15 min (900 s) with 8 nM EGF present. The
resulting total pERK and pAkt response are reported in Figure 3.2.
For both systems, implementing either a partially or completely speciﬁc branching quantitatively
yields the same downstream response, regardless of the degree of diﬀerential signaling. This observation validates our hypothesis that the diﬀerences in the downstream signaling between the WT
and mutant receptors stem from changes in the eﬃciency of C-terminal tail phosphorylation (i.e.,
kcat /KM values for the substrate tyrosines) rather than the speciﬁcities of the docking proteins to
phosphotyrosines. One notable feature is the 10-fold lower pERK levels in the mutant in the presence of a diﬀerential branched signaling, suggesting that speciﬁcity of the Y1173 peptide induces a
sensitivity in the ERK activation, but the degree of speciﬁcity (when present) is unimportant.

3.2.3

Robustness of Signaling

In a recent review, the ErbB signaling network is described as a bow-tie-conﬁgured (or hour-glass
shaped), evolvable network, displaying modularity, redundancy, and control circuitry [33]. This
framework suggests that identifying the targets proteins for eﬀective inhibition and the eﬀects
of the mutation landscape would require a systems level understanding of the signaling network.
Based on the protocol outlined in the methods section, we perturbed the network using our Monte
Carlo strategy and performed principal component analysis in the space of rate-constants as well as
on initial concentrations. In both cases, the top three modes constituted 99% of the scatter in the
parameter space. We then identiﬁed the components of the three principal eigenvectors (i.e., which
particular combination parameters render the network hyper-sensitive according to our measure.
There were several surprising features in our ﬁndings: (1) The components of the eigenvectors were
non-zero only as singlets or pairs, suggesting that the perturbation of only one or at most a combination to two parameters were driving the network hyper-sensitive; (2) The identiﬁed components
(Table 3.2), were insensitive to the degree of perturbation (i.e., the same components resulted irrespective of the extent of perturbation, σ of 0.3, 1.0, and 3.0; (3) The resulting components in
Table 3.2 clearly reﬂect the bow-tie-conﬁguration of the network; namely, the system is susceptible
to perturbation only at the top (and bottom, these are our measures for hyper-sensitivity), with
the middle (or core) layers robust to perturbations; (4) The top principal components identiﬁed
almost exclusively comprised of ATP binding and C-terminal tyrosine phosphorylation, thereby
justifying why the inhibition of receptor phosphorylation is likely to be an optimal target, and suggesting why mutations changing the (diﬀerential) phosphorylation kinetics can profoundly impact
the downstream response.
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Figure 3.2: Eﬀect of peptide speciﬁcity on activated ERK and Akt levels. The WT (A and B) and
mutant (C and D) systems were simulated for 15 min under the conditions indicated. Accumulated
(time-integrated) ERK-(p) (A and C) and Akt-(p) (B and D) levels were calculated as a function
of peptide speciﬁcity; 0.5 denotes 50/50 or no speciﬁcity (peptide binds equally to either tyrosine);
1.0 denotes 100/0 or perfect speciﬁcity (peptide binds only to its cognate tyrosine as described in
the text).
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Rate Constants
kf : Y1068
kf : Y1173
KM : ATP·RTK
KM : GAB·pEGFR
.
.

Initial Concentrations
[Raf·Ras·GTP]
phosphatase for pERK
[pMEK]
[PI3K inactive]
[MEK·Raf active]
[EGFR·Shc·Grb2·SOS·RasGTP]

Table 3.2: Parameter variations constituting the top three principal components for network
hyper-sensitivity.

3.2.4

EC50 for Inhibition of EGFR in the cell

Next, we examined the sensitivity of WT and mutant systems to inhibition in the cellular context by calculating receptor phosphorylation over a range of erlotinib concentrations. Simulations
were performed for both “normal” ([EGFR] = 100 nM) and “over-expressed” ([EGFR] = 1000
nM) systems. All simulations were performed with (50 ng/ml or 8 nM) or without ligand (EGF)
stimulation. The EC50 (inhibitor concentration at which 50% of the activity is suppressed in the
cellular context; this is diﬀerent from IC50 because the nonlinear and temporal eﬀects due to signaltransduction is accounted for) for L834R was 50-fold lower (Figure 3.3a,b) than that of the WT
(100 nM vs. 5000 nM) in the presence as well as absence of ligand. There were also no prominent
diﬀerences between the inhibition at 1068 and 1173 sites. In over-expressed systems, there was no
signiﬁcant diﬀerence in EC50 among the four groups (Figure 3.3c,d). All had an EC50 near 1000
nM.

3.2.5

Inhibition of Downstream Activation (EC50 )

We then examined the sensitivity of downstream signaling molecules ERK and Akt to inhibition for
a range of erlotinib concentrations (see Figure 4: a-d). In normal expression systems (Figure 3.4a,b),
there was a nearly 7-fold increase in the eﬃciency of pERK inhibition for L834R (EC50 = 100
nM) compared to WT (EC50 = 700 nM) with and without ligand present. With respect to Akt
activation, there was a 4-fold decrease in EC50 for L834R compared to WT (300 nM vs. 1200
nM) with and without ligand present. For the case of over-expressed receptors (Figure 3.4c,d),
inhibition of pERK is 4-fold more eﬃcient for L834R compared to WT, while pAkt inhibition is
almost 10-fold more eﬃcient for the L834R mutant, although signiﬁcantly more erlotinib is required
to achieve inhibition (EC50 =40 M). This result is consistent with the dramatically elevated Akt
levels expected in systems that bear both the L834R mutation and a higher receptor count.
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Figure 3.3: Relative inhibition of receptor phosphorylation: Tyr phosphorylation levels relative
to that without inhibitor are plotted.
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3.3

Conclusion

We have presented a framework to interpret the eﬀect of tyrosine kinase inhibitors on the systemwide cellular response. Through multiscale modeling, we have also shown how this framework can
be utilized to predict the eﬃcacy of inhibition in cell-lines, especially those harboring mutations in
the receptor. We ﬁnd that the mutant cell line is more susceptible to inhibition by TKIs through
the curbing of receptor phosphorylation and downstream (ERK and Akt) activation. Considering
that the absolute pAkt levels are 5-fold higher than those for pERK in the WT and 100-fold higher
in the mutant (Figure 3.1), the remarkable eﬀect of the drug in non-small-cell lung cancer cell lines
carrying the mutation can be attributed to the gain in eﬃcacy with respect to Akt inhibition. The
multiscale computational framework described here is ideal for assessing mutation landscape on
signal transduction. We believe that our model driven approach will in the long-term signiﬁcantly
impact the optimization of future small molecule therapeutic inhibition strategies.
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Figure 3.4: Inhibition of ERK and Akt activation in systems with normal receptor expression.
Responses plotted relative to that without inhibition under the same conditions.
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Chapter 4

Calcium and Phosphoinositide
Signaling in Human Platelets
4.1

Introduction

Platelets respond to endothelial injury or activating agonists by engaging a host of intracellular
signaling events, including receptor activation, G protein signaling, second messenger generation,
Ca2+ release, granule secretion, and cytoskeletal rearrangement [17, 150]. While the molecular
details underlying individual activation events are continually reﬁned through focused studies, it
has been diﬃcult to develop a uniﬁed and integrated view of platelet metabolism since it involves
a large number of simultaneously interacting molecular components. To this end, computational
models help provide an integrated view of the many interacting components involved in cellular
signaling [4]. Successful applications of the systems biology approach have led to an improved
understanding of cell surface receptors [15, 86], quantitative prediction of protease cascades in
blood coagulation [66,91,105], and the discovery of novel molecular interactions [136]. When based
on reliable data sets, accurate models have the potential to not only explain previously observed
behaviors, but to make experimentally veriﬁable predictions about how cells process biological
signals [74].
In many ways, the platelet provides an ideal test system for human systems biology. Platelets from
normal donors or patients are readily available for in vitro diagnostic research and clinical monitoring. Isolated platelets, platelet rich plasma, or whole blood are amenable to high throughput
experiments to study signal transduction and associated coagulation protease cascades. Additionally, numerous genetic mutations in humans [118] as well as knockout and transgenic mice [79, 137]
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are known that predispose to bleeding phenotypes. From a modeling perspective, the platelet is
particularly well-suited for study since it lacks a nucleus, allowing one to avoid the challenges of
describing whole-genome transcriptional regulation. Finally, the well-appreciated importance of
platelets in mediating thrombosis and hemostasis, as well as their contribution to systemic disorders such as inﬂammation and cancer [36], place a high practical value on an accurate platelet
model. Such a model would be useful both as a basic research tool for predicting normal activation
behavior and as a strategy for the rational design of patient-speciﬁc pharmaceutical therapies [92].
In this study, we describe a computational model of the human platelet that accurately predicts
both resting and activated system behaviors. The model is based on 24 peer-reviewed studies spanning three decades of platelet research. Because of the inherent complexity in a model of this size,
we ﬁrst constructed a set of four distinct signaling modules (see Chapter 5) to describe (i) Ca2+
release and uptake, (ii) phosphoinositide (PI) metabolism, (iii) P2Y1 G-protein signaling, and (iv )
protein kinase C (PKC) regulation of phospholipase C-β (PLC-β). Using ﬁxed reaction equations
and ﬁxed kinetic parameters, each module was tuned to match a relevant set of experimental data
by selecting allowable values for the resting concentrations of the module species. For the ﬁnal
analysis, the four modules were merged into a single kinetic model and ﬁt to Ca2+ release data
from ADP-stimulated platelets. Dynamic traces of intracellular Ca2+ represent multiple steps in
a complex signaling pathway from extracellular ligand to intracellular activation response, incorporating dynamic contributions from each module in the system. The fully integrated model was
capable of reproducing population and single-cell Ca2+ release data as well as measurements of PI
turnover and G protein activation.

4.2
4.2.1

Materials and Methods
ADP-stimulated Ca2+ release assay

Human blood was collected from healthy donors via venipuncture and anticoagulated with sodium
citrate (9 parts blood to 1 part sodium citrate). Platelet-rich plasma was incubated for 45 min
with Fluo-4 NW (Invitrogen) per the manufacturers instructions. PRP was diluted to a ﬁnal
concentration of 12% on a 384-well plate. A separate plate containing varying concentrations of
ADP was prepared on a PerkinElmer Janus. Intracellular Ca2+ concentration was quantiﬁed by
measuring F(t)/F0 using a Molecular Devices FlexStation. Results are the average time-series
measurements of 6 replicates. Phlebotomy was conducted in accordance with the Declaration of
Helsinki and under University of Pennsylvania Institutional Review Board approval.
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4.2.2

Platelet Image Analysis

High-resolution electron micrographs of platelets stained with glucose-6-phosphatase obtained from
Ebbeling et al. [46] were used to quantify the relative area of the dense tubular system (DTS)
with respect to cytoplasmic area. Stained areas were delineated by using a threshold value for
pixel intensity. To determine the sensitivity of the technique to the chosen threshold value, we
calculated the DTS area using a maximally inclusive threshold (all stained regions and some of
periphery included in delineation) and a minimally inclusive threshold value (delineation entirely
within stained portion of image). The range of results obtained by both threshold values did not
diﬀer by more than a factor of two.

4.2.3

Model Construction and Simulation

Ordinary diﬀerential equations (ODEs) were used to describe reaction rates corresponding to published reaction mechanisms and kinetic parameters (see Table 1 in ref. [129]). To eﬃciently estimate
the dynamic range of initial conditions (ICs), the abundance of each estimated species or compartment size was estimated over a base-10 logarithmic scale (as in Figure 4.3). For reactions occurring
at compartmental interfaces (e.g., cytosol and plasma membrane), reaction rates were adjusted by
scaling the concentrations of reactants to the bulk compartment as described by Kholodenko et
al. [86]. Within each of the ﬁve compartments, species were assumed to be well-mixed. While we
do not discount the importance of spatial gradients in Ca2+ signaling [177], previous studies have
shown that changes in [Ca2+ ]i within platelets are eﬀectively instantaneous [64]. Simulations were
performed using the SBToolbox for MATLAB [146] Numerical integration was performed with an
absolute tolerance of 10−45 and a relative tolerance of 10−9 .

4.2.4

Module Calibration and Analysis

The model topology was deﬁned by a set of reaction equations, rate laws, and kinetic constants
(see ref. [129] for a complete list of model reactions and rate constants). The concentrations of
all enzymes and metabolites in the resting platelet at homeostasis comprise the initial condition
(IC) space of the model. The topology of the Ca2+ signaling network and almost all other kinetic
parameters are known from literature [129] except for those describing P2Y1 activation, which
were calibrated from measurements of P2Y1 -reconstituted proteoliposomes (see 4.3). A subset of
IC space for each module was established by use of homeostasis constraints and experimental data
from platelets. The homeostasis constraint requires that a resting platelet remains resting such
that the initial condition is also a steady-state solution of a given set of ODEs (see Chapter 5). We
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performed a dense sampling of unknown ICs over ﬁxed reaction topologies to identify combinations
of IC values that were consistent with known steady-state concentrations.
Calculation of Ca2+ spiking frequency distribution. As described by Heemskerk et al. [64], strong
release events were identiﬁed by taking the derivative of the Ca2+ ﬂux traces and setting a noise
threshold above which peaks were considered to be signiﬁcant (Figure 4.8). Video-imaged platelets
were found to be quite variable both in peak interval times (4 to 40 s) and peak amplitudes (20
to 300 nM). We also observed signiﬁcant variability in the platelet model, with peak amplitudes
ranging from 100 to 300 nM (Figure 4.7C). We were unable to estimate a single dominant frequency
using Fourier transform analysis of the simulated Ca2+ traces because of the substantial noise
and irregularity of spiking. Half-maximal agonist dose (1 μM) was used to generate a frequency
distribution for desensitized platelets treated with antagonists prostaglandin I2 , apyrase, and aspirin
prior to 20 μM ADP.

4.3
4.3.1

Results
Model Overview

The full model (Figure 4.1, ref. [129]) comprises four interlinked kinetic modules (Figure 4.2AD). The Ca2+ module (Figure 4.2A) spans ﬁve compartments and functions to maintain a low
intracellular Ca2+ concentration ([Ca2+ ]i ) by pumping ions across the PM into the extracellular
space, or across the membrane of the DTS into platelet stores using a sarcoplasmic/endoplasmic
reticulum Ca2+ ATPase (SERCA). Inositol trisphosphate receptor (IP3 R) channels release Ca2+
from the DTS and are regulated by inositol 1,4,5-trisphosphate (IP3 ) and Ca2+ i . In the PI module (Figure 4.2B), membrane-derived signaling intermediates such as IP3 are continually recycled
between the plasma membrane (PM) and cytosol by a series of phosphorylation, dephosphorylation, synthesis, and hydrolysis reactions [129]. Among its hydrolysis products, PLC-β generates
PM-bound diacylglycerol (DAG), which, along with Ca2+ i , modulates the activity of PKC. PKC
dampens GPCR-mediated signaling by phosphorylating PLC-β, reducing its hydrolytic activity. In
a module for receptor activation (Figure 4.2D), free ADP in the extracellular compartment binds
to the G protein-coupled receptor (GPCR) P2Y1 , causing a subsequent rise in activated G protein
(Gq ·GTP). Gq ·GTP has a basal rate of hydrolysis that is accelerated when it is bound to PLC-β.
The transient complex PLC-βGq ·GTP (PLC-β∗) is the hydrolytically active form of the enzyme
and regulates transmembrane signaling in the PI module.
Clearly, the model does not include all of the reactions that govern platelet homeostasis and activation. Such a list is both unavailable and intractable to deploy until a core set of modules can be
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Figure 4.1: Schematic of platelet model compartmentalization and reactions. The full model
comprises 5 compartments, 70 species, 77 reactions, and 132 kinetic parameters [129]. 3D compartments: extracellular (EX), cytosolic, and DTS. 2D compartments: PM and DTS inner membrane (IM). Abbreviations: IPP, Inositol phosphate phosphatase; IP2 P, Inositol bisphosphate phosphatase; IP3 P, inositol trisphosphate phosphatase; DAG, diacylglycerol; PA, phosphatidic acid;
CDP, CDP-DAG.

validated, which is the focus of this study. We have focused on the subset of reactions that govern
ADP-mediated phosphoinositide signaling and mobilization of intracellular Ca2+ [129]. The P2Y1
receptor is coupled primarily to the Gq family of G proteins,20,21 which activate the beta-isoform
of phospholipase C [17, 82]. Previous work has shown that this pathway accounts for more than
90% of the ADP-mediated Ca2+ signaling in platelets [138]. To eliminate Ca2+ inﬂux and the need
to model store-operated Ca2+ entry, we used experimental data from studies in which extracellular
Ca2+ was removed by EDTA or another chelating agent. EDTA was also used in our own experiments. ADP releases Ca2+ only from the DTS [104] and thus modeling the acidic store is not
required at this point.

4.3.2

Platelet Ca2+ Balance

The Ca2+ module addresses a fundamental question of what resting level of IP3 is needed to
balance the open probability of IP3 R channels with SERCA in a platelet of a given DTS volume
and [Ca2+ ]dts . Our strategy for modeling platelet Ca2+ signaling can be summarized in two steps:
First, we considered the kinetic properties of the IP3 R and SERCA [45,154,186], the resting Ca2+ i
concentration [150], and the volume of the platelet [174] to be accurate as reported. These values
were held ﬁxed in the module. Second, we generated more than 109 combinations of the unknown
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Figure 4.2: Detailed reaction schemes for platelet signaling modules. (A) Ca2+ Module: cytosolic
and DTS compartments are separated by the DTS membrane, which contains the IP3 R and SERCA.
(B) PI Module: PM-bound PIs are cleaved by PLC-β to form diﬀusible inositol phosphates and
DAG, which are substrates for resynthesis of PIs. (C) PKC Module: Ca2+ i and DAG activate PKC,
which migrates to the PM where it phosphorylates PLC-β. (D) P2Y1 Module: extracellular ADP
binds to and activates P2Y1 . Active P2Y1 accelerates guanine nucleotide exchange on bound Gq .
Gq ·GTP binds and activates PLC-β, which increases the GTPase activity of Gq ·GTP. (E) SERCA
catalytic cycle [45]: Subscripts: E1, facing cytosol; E2, facing DTS; P, phosphorylated. (F) IP3 R
dynamics [154]: Subscripts: n, native; i1, inhibited; o, open; a, active; s, shut, i2, inhibited. (G)
PKC activation: Active kinase is bound to Ca2+ i and DAG and located at the PM. Subscripts: M,
located at the PM; C, Ca2+ -bound; D, DAG-bound. (H) P2Y1 activation module: Rate equations
describing the interactions among ADP, P2Y1 , and Gq were modeled according to the ternary
complex model described in Kinzer-Ursem et al [87]. For clarity, DTS membrane and cytosolic
compartments are not delineated. Abbreviations: A, ADP; P, P2Y1 ; G, Gq . ∗Ca2+ both activates
and inhibits IP3 R [154].
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values in the module (number of IP3 R/platelet, SERCA pumps/platelet, [Ca2+ ]dts , volume of
the DTS) to ﬁnd a set of “conﬁgurations” that reached an equilibrium state with the known
resting [Ca2+ ]i (see 4.2). Each conﬁguration may be thought of as a unique platelet model with a
characteristic compartmental structure and molecular makeup (i.e., diﬀerent numbers of SERCAs,
IP3 Rs, etc). Note that more than one module conﬁguration can produce the same resting [Ca2+ ]i .
Existing kinetic, electrochemical, and physiological data was incorporated into the module as follows: Resting platelets maintain a [Ca2+ ]i between 40-100 nM [64, 150], while storing concentrated
Ca2+ ([Ca2+ ]dts ) in the DTS [150]. Pumping of Ca2+ by SERCA isoforms (Figure 4.2E) was modeled according to a kinetic study of the type 3 SERCA isoform [45], which is abundant in human
platelets [93]. For the IP3 R [154], each subunit of the type 2 receptor exists in one of six states: native, open, shut, active, or two inactive states (Figure 4.2F), where state transitions depend on [IP3 ]
and [Ca2+ ]i . The channel open probability (Po ) is determined by the number of IP3 R tetramers
with all subunits in either open or active conformations [129]. We used the Nernst equation [2] to
relate Po to the release of Ca2+ from the DTS:
d[Ca2+ ]i
RT
= N Po γe
ln
dt
zF



[Ca2+ ]dts
[Ca2+ ]i


(4.1)

Here, N is the total number of channels per platelet, γ is the single-channel conductance (10 pS)
of the platelet IP3 R [186], and e is the number of elementary charges (z) per second per Ampere
(6.24 × 1018 ). The cytosolic volume of the platelet is ≈6 fL [174].
The unknown quantities in the module were the number of IP3 R and SERCA per platelet, [Ca2+ ]dts ,
and the volume of the DTS. The range of values sampled for each quantity is shown in Figure 4.3A.
A dense sampling (n = 109 ) of these quantities generated 100,000 unique conﬁgurations of the
Ca2+ module (with [Ca2+ ]i = 100 ± 10 nM) that were further divided into three groups (low, mild-, and high-response) based on the estimated [Ca2+ ]dts , an indicator of the conﬁgurations
response to an increase in [IP3 ] (Figure 4.3B). To examine any molecular or structural diﬀerences
among low-, mild-, and high-response groups, we compared the levels of SERCA, IP3 R, IP3 , and
relative DTS volume that were estimated for each group. These values are presented as probability
distributions (Figure 4.3C), where regions of high density reﬂect frequently occurring values for
the estimated concentrations and compartment sizes. For example, low response conﬁgurations
tended to have ≈ 1000 IP3 R channels per platelet as indicated by red regions (Figure 4.3B). We
note that, of 109 sampled conﬁgurations, only 0.005% satisﬁed the dual constraints of steady-state
Ca2+ homeostasis and IP3 responsiveness (mild- or high-response conﬁgurations). This observation
indicated that the kinetic properties of Ca2+ -regulating enzymes such as IP3 R and SERCA alone
place strong constraints on the physical size and molecular makeup of the platelet.
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Figure 4.3: Estimation and analysis of platelet Ca2+ regulation. Unknown concentrations and
compartment sizes in the platelet Ca2+ module were estimated by randomly sampling the unknown
quantities in panel A and selecting only those molecular “conﬁgurations” that produced a resting
[Ca2+ ]i of 100 ±10 nM. (B) This reduced set of conﬁgurations was divided into 3 groups based on
the estimated [Ca2+ ]dts (top), which corresponded to the [Ca2+ ]i release behavior after a 10-fold
increase in [IP3 ] (bottom). (C) Probability distributions for estimates of SERCA, IP3 R, IP3 , and the
relative DTS volume in low-, mild-, and high-response conﬁgurations (n = 100, 000). The measured
IP3 level from resting platelets [161] is boxed. (D) Image obtained from glucose-6-phosphatase stain
of the DTS from a human platelet [46] was used to quantify the cytosolic (gray) and DTS (black )
area from a 2D section of the platelet.
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Conﬁgurations with a negligible gradient ([Ca2+ ]dts ≈ 100nM) lacked IP3 -responsiveness and had
relatively low SERCA levels (67% had ¡ 5000 copies) with a median estimate of 1600 IP3 R channels/platelet. By contrast, mild-response conﬁgurations ([Ca2+ ]dts ¡ 10 μM) responded to elevated
[IP3 ] with a transient rise in [Ca2+ ]i and were characterized by high SERCA levels (≈ 106 /cell) and
higher IP3 R abundance (median = 2000 channels/cell). High-response conﬁgurations ([Ca2+ ]dts ¿
10 μM) clustered near 106 SERCA pumps but showed a broad distribution of IP3 R abundance.
The calculated IP3 R/SERCA ratio for low-response conﬁgurations had a loosely deﬁned distribution, while the mild- and high-response conﬁgurations favored 103 -105 more pumps than channels (1:6900 for mild-response and 1:5200 for high-response). Thus, the model predicted a very
low IP3 R/SERCA ratio for functioning platelets, a hypothesis supported by noting that a single
SERCA3b pump operating at a membrane with a 1000-fold Ca2+ gradient transports ≈0.4 Ca2+
ions/s [45], while a single type 2 IP3 R channel in the same membrane at 37◦ conducts ≈3,000 Ca2+
ions/s, assuming a steady-state Po of 0.0005 [154].
The low-response conﬁgurations harbored high resting concentrations of IP3 , inconsistent with a
resting platelet [16]. The median IP3 count for mild-response conﬁgurations was 750 molecules/cell,
similar to the measured value (≈1200 molecules/platelet or ≈ 200 nM) [161] in resting platelets.
More than 80% of high-response conﬁgurations harbored ¡1000 IP3 molecules/cell in resting platelets.
The relative volume of the DTS compartment to cytosol, as predicted from the estimation procedure, was quite constrained at 0.5-5% (median = 2%) of the non-granular intracellular volume. To
compare this result to a direct physical observation, we quantiﬁed the relative area of the platelet
DTS as revealed by glucose-6-phosphatase staining [46]. This calculation gave a DTS/cytosol fraction of 4.3%. Assuming the stained region marks the true DTS border, this estimate is accurate
within a factor of two (see Section 4.2). Thus, estimates obtained from independent kinetic calculations or image analysis of stained platelets gave similar values for the DTS compartment volume
fraction.

4.3.3

PI Metabolism

PIs are continually interconverted in platelets, even under resting conditions [16, 150, 176]. To
capture this behavior, we employed a set of synthesis and degradation reactions that continually
recycles PIs in the absence of a stimulating dose of agonist (Figure 4.2B, [129]). Failure to account
for PI resynthesis would have prevented prediction of steady-state concentrations. Using the same
strategy for modeling platelet Ca2+ regulation (see Section 4.3.2), we generated 10,000 unique PI
module conﬁgurations that were consistent with the measured resting concentrations of PtdIns,
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Figure 4.4: Comparison of PI and P2Y1 modules to experimental data. (A) At t = 0, platelets
were treated with 27 nM thrombin and the levels of PtdIns, PIP, and PIP2 were measured (data
obtained from Wilson et al. [176]). To simulate this turnover in the PI module, [PLC-β∗] was
raised to 1 μM and PI levels were calculated over time. Average results from 100 simulations are
plotted as solid lines. (B,C) Kinetic parameters in the P2Y1 module were ﬁt to GTP hydrolysis
measurements from proteoliposome assay containing 300 nM P2Y1 , 1 μM Gα·GDP, 3 M Gβγ,
2 μM GTP, RGS4, and 2MeSADP (data obtained from Waldo et al. [169]). Best-ﬁt simulation
results are plotted as solid lines. (B) Time-course GTPase activity is shown with (filled squares)
or without (open squares) 100 nM RGS4. (C) P2Y1 dose-response to 2MeSADP in the absence
(open squares) or presence (filled squares) of 100 nM RGS4. In the ﬁnal platelet model, Kd and
kcat values for ADP-binding and PLC-β-mediated hydrolysis, respectively, were substituted for the
2MeSADP- and RGS4-mediated activities used in the calibration procedure shown here.

PIP, PIP2 , DAG, and PA [126, 168, 176]. Thus, each conﬁguration represents a potential molecular arrangement of PIs in the platelet that is consistent with published kinetic rates and resting
measurements for key membrane phospholipids.
To examine the transient behavior of the PI module under activating conditions, we set the concentration of PLC-β∗ in the module to 1 μM (≈100-fold above basal levels). Figure 4.4A compares
the measured and simulated changes in the platelet PIs after treatment with thrombin or elevated
PLC-β∗, respectively (both thrombin and ADP signal through Gq -mediated stimulation of PLCβ1). The simulated time course for PtdIns degradation was consistent with experiment throughout
the 90 s interval following activation. Simulated levels of PIP and PIP2 were consistent with
experiment [176] through the ﬁrst 25 s (Figure 4.4A). After this time, PIP and PIP2 continued
to be degraded in the simulation but were sustained, or slightly elevated, in thrombin-stimulated
platelets. A recent study in murine megakaryocytes [170] has conﬁrmed that resynthesis of PIP2
is necessary to replenish basal levels following agonist stimulation, a feature that is included in the
model. However, because the rate of hydrolysis exceeds the rate of PI synthesis, we observed a
monotonic decrease in PIs when the level of PLC-β∗ was held ﬁxed. To address this discrepancy
between model and experiment, we introduced a negative-feedback module (see Signal Attenuation, Figure 4.2C) in which the activity of PLC-β∗ is attenuated by activated PKC (PKC∗) through
phosphorylation of the phospholipase.
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4.3.4

Signal Attenuation

As noted above, the degradation of PIs in platelets following PLC-β activation does not decrease
monotonically [150, 176]. Furthermore, the sharp rise in [IP3 ] and [Ca2+ i ] following GPCR stimulation returns to near-basal levels within 30-60 s [43]. This negative-feedback mechanism was
modeled by allowing direct inactivation of PLC-β by PKC through a phosphorylation reaction,
which has been observed in several cell types [55, 135]. In the PKC module (Figure 4.2C), activation of the kinase requires association with Ca2+ i and DAG and translocation to the PM [13].
Activated PKC (PKC∗) phosphorylates PLC-β, rendering it unable to bind Gq ·GTP. Clearly, this
represents only one of several potential mechanisms for regulation of Gq -dependent PI hydrolysis in
platelets. Other mechanisms include receptor internalization [11], deactivation of G proteins [17],
and accelerated dephosphorylation of IP3 [37]. While these mechanisms will provide useful contributions to future iterations of the platelet model, it is interesting that the use of PLC-β regulation
was suﬃcient to reproduce the observed attenuation in PI signaling following agonist stimulation
(see Figure 4.5C,D). Speciﬁcally, the gradual accumulation of Ca2+ and DAG during the ﬁrst 10-15
seconds provides the appropriate time-delay for shutting oﬀ PIP2 hydrolysis.

4.3.5

Receptor Activation

P2Y1 is a GPCR expressed on the surface of human platelets (≈ 150 copies/platelet [12]) that is
essential for ADP-induced platelet shape change and aggregation [82]. Although other ADP receptors are involved in platelet Ca2+ signaling (e.g., P2X1 and P2Y1 2), P2Y1 contributes ¿90% of
the Ca2+ signal [138]. In our representation of P2Y1 activation (Figure 4.2D,H), binding of extracellular ADP to P2Y1 leads to activation of Gq through GDP/GTP exchange reactions. Gq ·GTP
is a substrate for GTPase activating proteins (GAPs) such as PLC-β and RGS4, which can accelerate Gq ·GTP hydrolysis over 1000-fold [114]. Bornheimer et al. showed that the combination of
G proteins, active GPCRs, and GAPs can form kinetic “ternary” modules with distinct signaling
patterns [15]. Thus, we used results from a published in vitro assay of P2Y1 activity to construct
a ternary model of the P2Y1 receptor. In that assay, Waldo et al. combined puriﬁed human P2Y1 ,
ADP, Ga and Gβγ subunits, PLC-β or RGS4, and radiolabeled GTP in large phospholipid vesicles
and measured the agonist binding and Gq -stimulating activities of the receptor [169]. GTPase
activity was measured with and without agonist (Figure 4.4B). ADP dose response was measured
with and without GAP protein (Figure 4.4C). Using identical simulated conditions, we obtained
the kinetic parameters in the P2Y1 module from these time-course measurements. The kinetic
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rate constants, given in Table 1 of ref. [129], accurately reproduced both sets of measurements
(Figure 4.4B,C).

4.3.6

Signaling in Platelet Populations

The four modules described above were merged into a single kinetic model using a bootstrap method
(Figure 4.6). With a ﬁxed reaction network (Figures 4.1 and 4.1) and ﬁxed kinetic rate constants
[129], initial conditions were ﬁt to dose-response [Ca2+ ]i time-course data from ADP-stimulated
platelets (Figure 4.5A,B). In the presence of basal ADP levels similar to human venous plasma [8],
the model maintained a resting [Ca2+ ]i of 75 nM (Figure 4.5B). At higher ADP concentrations,
[Ca2+ ]i reached peak levels ≈ 20 s after addition of agonist with a decay constant of ≈1 min. We
found the synchronous [Ca2+ ]i peak-response at all agonist doses to be a complex and unique feature
in the data, particularly well-suited for testing model validity. Achieving this characteristic shape
required a transient (non-monotonic) rise in [IP3 ]. In ADP- and thrombin-stimulated platelets
[43, 132], [IP3 ] increases rapidly after agonist addition, peaks around 15 s, and then decreases to
near-basal levels. The model predicted this behavior accurately (Figure 4.5C). We observed that
PLC-β∗, which comprised ≈ 0.2% of the total PLC-β pool in the model, strongly controlled this
rise and fall of [IP3 ] (Figure 4.5C,D). Phosphorylation of inactive PLC-β by PKC∗ (Figure 4.5E)
was suﬃcient to dampen Gq -mediated PI hydrolysis. The simplicity of this negative-feedback
model suggests a mechanism whereby the phosphorylation of inactive PLC-β, present at much
higher abundance than PLC-β∗, ﬁne-tunes the hydrolytic activity of the enzyme by sequestering
it from Gq ·GTP. Addition of ADP caused a sharp burst in [Gq ·GTP] that saturated within 510 s for all doses (Figure 4.5F). This trend was consistent with the observed time-scale for G
protein activation [87]. Maximal [Ca2+ ]i and [IP3 ] responses to increasing ADP was predicted
quantitatively (Figure 4.5G,H).

4.3.7

Signaling in Individual Platelets

Deterministic simulations, such as those in Figure 4.5B-F, resemble data obtained from suspensions of platelets (Figure 4.5A), in which a million or more cells may be assayed simultaneously.
These conditions often produce average or “smooth” responses that are typical of cell populations.
However, when platelets are monitored individually, the addition of agonist can produce a series of
sharp, asynchronous Ca2+ spikes [63,64]. To test the single-platelet response in the model, we used
the Stochastic Simulation Algorithm [59] to simulate Ca2+ release in a single platelet during rest or
activation by ADP. Using the estimated sizes of the platelet compartments, species concentrations
were converted to integer values for use in the stochastic simulation. Note that any species present
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Figure 4.6: Modular calibration and feature extraction. (A) Example construction of a functional
module, showing calibration of platelet Ca2+ balance. A ﬁxed reaction network containing one or
more unknown ICs (e.g., the concentration of a protein or the size of a compartment) was simulated
to equilibrium using a large number of random value-sets. The output of each simulation was
compared to experimentally measured values, and value-sets with low error (±10% of experimental
values) were selected as “points” in the module space. Principal components analysis (PCA)
was then used to transform these points to a new coordinate set that maximally describes the
variability in the module. (B) Simulated release of intracellular Ca2+ for sampled points along the
ﬁrst principal component. Traces show the ﬁrst second of Ca2+ release after a ten-fold increase in
IP3 . See Chapter 5 for a detailed description of the method.

at 1 nM in a 6 fL platelet constitutes less than 4 molecules, a level that can give rise to stochastic
ﬂuctuations.
Dramatic, asynchronous [Ca2+ ]i spikes increased in frequency and amplitude after activation with
ADP (Figure 4.7A,B). Before agonist stimulation, the resting platelet model showed occasional
Ca2+ spikes with relatively small amplitude. Similar behavior was noted in a third of recorded
platelets [63], which spiked on average 1.6 ± 0.2/min without ADP stimulation. The onset of Ca2+
release after agonist addition was rapid in the model (≈5 s) and persisted for several minutes, also
consistent with experimental results [63,64]. Key drivers in this asynchronous spiking were the channel open probability, the low copy number of IP3 R channels, the size of the cytosolic compartment
(8 fL in the model), and the large Ca2+ gradient at the DTS membrane. To determine the frequency distribution of Ca2+ spiking, we followed exactly the empirical strategy used by Heemskerk
et al. [64] to distinguish individual Ca2+ release events in a detailed study of video-imaged platelets
(see Figure 4.8). There was a striking resemblance between simulation and experiment for the peak
interval distribution (Figure 4.7C), with the most common intervals occurring at 6-8 s or 11-13 s.
As platelet volume was artiﬁcially increased 100-fold in the stochastic simulation (Figure 4.7D),
the Ca2+ spiking was lost and typical, smooth ADP responses (as in Figure 4.5B) for populations
emerged. Thus, the asynchronous spiking appeared to be a result of the fundamentally stochastic
nature of signal transduction in cells as small as human platelets.
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Figure 4.7: Stochastic simulation of a single platelet. (A) A single, fura-2-loaded platelet was
immobilized on a ﬁbrinogen-coated coverslip and activated with 40 μM ADP at t = 90. Ca2+ i
trace was obtained from Heemskerk et al [63]. (B) After 90 s of simulated rest, the platelet model
was activated by setting extracellular [ADP] to 40 μM. [Ca2+ ]i was sampled every 0.1 s. (C) Single
platelets were simulated for 10 min and [Ca2+ ]i was sampled once per second. Ca2+ peaks were
identiﬁed as described by Heemskerk [64]. Peak intervals between 5 and 30 s were counted from 10
simulations as described for video-imaging studies (see Figure 4.9). Interval times were binned in
2 s increments for direct comparison with experiment (inset ). (D) The platelet model compartment
sizes were artiﬁcially scaled to 1, 10, or 100 times their original sizes. Simulation results are shown
for 300 s stochastic simulations with 20 μM ADP added at 90 s. The bottom plot shows results for
the deterministic simulation.

53

300

[Ca2+]i (nM)

A

1 μM ADP

200

100

[Ca2+]i (nM s-1)

0

B

20

noise threshold

0

d
dt

−20
0

50

100

150

200

250

300

350

Time (s)

Figure 4.8: Calculation of Ca2+ spiking frequency distribution. (A) 600 s Ca2+ i traces from 100
stochastic simulations were sampled every 1 s. (B) The derivative of each trace was calculated, and
a noise threshold of 10 nM s-1 was used to count the peak-to-peak interval times for each trace.

4.4

Discussion

We deployed available kinetic data, electrochemical calculations, measurements of cell size, and
modular organization of signaling function to estimate the physical structure and dynamical properties of ADP-stimulated Ca2+ release in human platelets. For the ﬁrst time, a single model has
accounted for several fundamental attributes of known platelet behavior: (i) In the presence of
basal ADP levels, the model remained at steady state and accurately predicted the resting concentrations of Ca2+ i , IP3 , DAG, PA, PI, PIP, and PIP2 . Under these conditions, the model underwent
slow turnover of signaling molecules (e.g., IP3 , PLC∗, and Gq ·GTP), yet the rates of synthesis and
degradation of these metabolites were exactly balanced. At the same time, Ca2+ was continually
leaked from the DTS and actively pumped back into stores, maintaining a resting platelet [Ca2+ ]i
near 100 nM. This “active” homeostatic state is representative of the situation in vivo, since inhibition of SERCA pumps causes a gradual depletion of Ca2+ stores [150]. (ii) Increased [ADP] caused
a transient rise in [Ca2+ ]i and [IP3 ] with the correct dose response and time-course proﬁles. (iii)
Stochastic simulation of the platelet model generated noisy Ca2+ release and reuptake behavior
with a nearly instantaneous onset. (iv ) Calculation of peak-to-peak interval times revealed a distribution of intervals favoring 6-8 and 11-13 s gaps. These results were strikingly similar to what was
observed in video-imaged platelets and demonstrate that both averaged and stochastic behaviors
may be accurately captured by the same molecular model. Importantly, the model fulﬁlled the
dual requirement of maintaining homeostasis under resting conditions while remaining capable of
generating an activation response in the presence of suﬃciently high agonist concentration. This is
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a critical quality to consider when modeling platelets, which must be sensitive enough to respond
to injury without activating prematurely [17, 150].
Our analysis also produced several novel predictions: (i) The number of SERCA pumps was predicted to outnumber IP3 R channels (¡5000 IP3 R copies were predicted in most conﬁgurations).
This was largely a consequence of the kinetic properties of the enzymes, which transport Ca2+
at signiﬁcantly diﬀerent rates. (ii) The relative volume of the platelet DTS was predicted to be
2-4% of the non-granular intracellular volume, both by kinetic modeling and image analysis of a
DTS-stained platelet. (iii) Lower resting [IP3 ] was associated with greater [Ca2+ ]dts and more
acute Ca2+ release. (iv ) Restoration of basal PI levels following PLC-β∗ hydrolysis was predicted
to occur in part through a negative-feedback mechanism in which PKC∗ phosphorylates PLC-β
and thereby diminishes its hydrolytic activity. (v ) By artiﬁcially increasing the volume of the simulated platelet, we were able to quench the ﬂuctuation of Ca2+ spikes, achieving a response more
similar to that of megakaryocytes, in which regular oscillations in [Ca2+ ]i are observed with ﬁxed
amplitude and frequency [162]. Since mature megakaryocytes are more than 1000 times larger than
platelets [69], these observations suggest that the asynchronous and stochastic Ca2+ response in
platelets may simply be the consequence of a small intracellular volume.
The model also provided some insight into why thrombin is a more potent agonist than ADP.
Both agonists act through Gq -coupled GPCRs [17], yet there are about 10 times as many thrombin
receptors as ADP receptors [12, 17]. To determine whether the increased potency of thrombin
may be due to greater receptor surface expression, we increased the number of P2Y1 receptors
in the model and examined the ADP response. A 10-fold increase in [P2Y1 ] caused a 2-fold
higher peak response and more sustained elevation of [Ca2+ ]i (Figure 4.9), similar to the observed
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diﬀerence between thrombin- and ADP-stimulated platelets. While a more thorough analysis will
involve examining the coupling eﬃciency to Gq and the duration of the receptor active state, these
calculations imply that the low copy number of P2Y1 may be a limiting factor for ADP signaling.
Our estimation procedure generated 10 individual platelet models (unique sets of initial conditions
representing the resting concentrations for the 70 species in the model) that each satisﬁed homeostasis constraints and ﬁt all available data (Figure 4.10). These models may be thought of as
individual cells in a platelet population that vary in their exact molecular makeup but are each
capable of generating the same activation response. For certain species such as Ca2+ i , DAG, and
PIP2 , the similarity among the models can be easily explained since these quantities were held
ﬁxed (with a small variability term) to the values reported in the literature. Other similarities
in the concentrations, as for GTP and PLC-β∗, are more interesting because these values were
not explicitly restricted by the estimation procedure. Rather, these uniformities reﬂect implicit
constraints in the platelet model that emerged because of other species concentrations or signaling
reactions that strongly control the production or consumption of these species. As such, these
quantities are predicted to be rigid, or inﬂexible, “nodes” in the model [105] and are subject to
further investigation as a new hypothesis revealed by the analysis. By contrast, we observed several instances of variability in concentrations (node ﬂexibility) among the 10 models. For example,
the concentrations of PKC and Gq ·GTP both varied over 3 orders of magnitude. Similarly, the
values for P2Y1 , SERCA, PMCA, PLC-β, Ins, IP2 , and CDP·DAG varied appreciably. The large
variability observed for many of the estimated phospholipids (e.g., Ins, IP2 , and CDP·DAG) was
due to allowable node ﬂexibility and/or insuﬃcient experimental data to constrain the estimation
of the resting concentrations. Thus, while the essential steady-state and activation properties were
accurately captured by the module as a whole (Figure 4.4A), additional experimental data will be
necessary to generate reliable estimates for individual phosphoinositides. Finally, the estimated
number of IP3 R channels was generally low (¡2500 channels/cell) as expected from the analysis of
the Ca2+ module. Higher [Ca2+ ]dts appeared to be compensated by higher SERCA levels.
Through a computational analysis of the human platelet, we have demonstrated the successful integration of heterogeneous data sets and legacy knowledge to construct a predictive model of platelet
homeostasis and activation. This assembly of molecular detail represents, for the ﬁrst time, a
substantial description of the platelet signaling apparatus and was capable of reproducing diverse
experimental observations as well as providing speciﬁc, testable hypotheses regarding platelet enzymatic regulation, the physical structure of the cell, and the dynamics of intracellular calcium
release. Speciﬁcally, this is the ﬁrst work to provide a quantitative molecular explanation of the
asynchronous calcium spiking observed in stimulated human platelets. By incorporating additional
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experimental data, future versions of the model can include mechanisms for store-operated Ca2+
inﬂux mechanisms, the acidic Ca2+ store, integrin activation, granule secretion, phosphatidylserine
exposure, as well as additional receptors for prostacyclin, nitric oxide, thromboxane, epinephrine,
thrombin, ﬁbrinogen, and collagen. As experimental investigation of platelet function continues,
new data will be used to challenge, conﬁrm, and expand the platelet signaling model presented
here.
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Chapter 5

Steady-State Kinetic Modeling
5.1

Introduction

Computational models help quantify the reaction dynamics and regulatory modes in complex biochemical systems [4,7,9,13,50], particularly when a system is so intricate that its behavior cannot be
predicted by intuition alone. The building blocks for constructing large reaction networks are often
available in numerous databases [10,83,108,152] and journal archives. Here, one can obtain many of
the experimentally-derived elementary reaction steps, kinetic constants, or rate laws for individual
steps in a given biochemical system or pathway. Despite this wealth of information, however, compiling these data to construct models with accurate system-wide behavior represents a signiﬁcant
challenge in systems biology [70, 81]. Comprehensive models of metabolism have been successfully
developed for microbial systems [49, 50, 139] and a few eukaryotic cell types [145, 155, 175]. These
constraint-based models [88] are often represented by stoichiometric networks that lack an explicit
description of substrate concentrations, reaction mechanisms, or the transient behavior of the system. Although various strategies have been proposed to incorporate these features into large-scale
models [124, 153], the task of assembling complex kinetic models with nonlinear dynamics remains
a diﬃcult problem. One of the major obstacles to building accurate kinetic models is the number of
unknown parameters in the model that must be estimated using experimental datasets [153], which
themselves are often massive, incomplete, noisy, and/or imperfect [76]. A number of parameter estimation methods, such as genetic programming, simulated annealing, and various gradient-based
routines [111,127], have been proposed to infer unknown quantities in biochemical models. Most of
these methods address the problem of estimation in purely abstract terms and do not take into account the unique mathematical features of biochemical systems, such as a well-characterized kinetic
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subsystem (e.g., the dynamics properties of an ion channel [154]). Estimated parameters must still
meet constraints imposed by the other experimentally measured parameters in the model.
To address these challenges, we propose a strategy for assembling large kinetic networks that retain
the nonlinear dynamics governing individual reactions in the system. The key features of the method
are: (i) restriction of steady-state values by subsystem kinetics, (ii) reduction of the steady-state
solution space by principal component analysis (PCA), and (iii) combination of independently
constructed submodels (modules). The ﬁrst feature is a Monte Carlo sampling over unknown
concentrations with ﬁxed kinetic parameters derived from the literature. The opposite strategy has
been used in microbial systems to restrict kinetic parameters based on species concentrations [49].
The second feature, reduction of the steady-state space by PCA, has been applied previously for
metabolic systems described by a stoichiometry matrix [50, 139], but not, to our knowledge, for
nonlinear systems. In the last step, a full model representation is assembled by combining PCAreduced, steady-state solutions from each module to form a combined steady-state solution space
for the entire system. This global space may then be searched for solutions with accurate timedependent behavior using any number of established routines [61, 127].
The method exploits three properties common to many biological systems: modularity, homeostasis, and known quantitative kinetic relationships among interacting molecular components. Interestingly, this physiology-inspired approach enforces natural constraints on the range of allowable
system states and allows one to monitor shifts in steady states due to kinetic perturbations. To illustrate the method with an example, we show how 77 reactions from 17 primary data sources were
integrated to construct an accurate model of intracellular calcium and phosphoinositide metabolism
in the resting and activated human platelet. Finally, we extend our analysis of this modeling approach by examining the steady-state characteristics of a system that is aﬀected by changes in
kinetic rate constants.

5.2
5.2.1

Materials and Methods
Model Deﬁnitions and Requirements

Our method builds upon a common representation of biochemical reaction networks [38] consisting
of a system of ordinary diﬀerential equations (ODEs). In this paradigm, the concentration of
each molecule in the system changes with time as a function of the instantaneous values of other
concentrations and ﬁxed kinetic parameters in the model. We separate this model description
into two parts: The concentration vector (CV) of the model refers to the set of all molecule
concentrations at a given instant in time and is denoted by the vector c:
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c = (c1 , c2 , . . . , cn )

(5.1)

The model topology refers to the entire set of kinetic parameters and rate equations that determine
how these concentrations evolve with time. Mathematically, this is represented by the vector
function f , which deﬁnes the rate of change of c with time as a function of the model concentrations
and rate parameters:
⎡

⎤
f1 (c)

⎢
⎢
⎢ f2 (c)
dc
= f (c) = ⎢
⎢
dt
⎢ ...
⎣
fn (c)

⎥
⎥
⎥
⎥
⎥
⎥
⎦

(5.2)

The functional form of each fi is a sum of rate equations for each reaction that consumes or
produces ci and will generally vary for each molecule. Typical functional forms for f may include,
for example, a series of Michaelis-Menten or nonlinear rate expressions. A simple reaction topology
is shown in Figure 5.1A with corresponding ODEs in Figure 5.1B. It is useful to separate a large
model into two or more modules with subset CVs that overlap at reaction edges, as shown in
Figure 5.1A.
Often, the topology of a biological system is better characterized than its CV [88]. For example, the
major protein-protein interactions in a signaling pathway may be deduced from mutation or knockout studies, providing a molecular wiring diagram that links together the various components in the
network. For each of these interactions, puriﬁed enzymes may be used to measure the strength of
the interaction in vitro or to measure the rate of some enzyme-catalyzed reaction in the system. An
important caveat is that the kinetic rate constants within the cellular milieu (the cell context) may
be diﬀerent from those obtained in an in vitro experiment with puriﬁed components. In contrast, it
is generally more diﬃcult to accurately measure the absolute abundance of intracellular enzymes or
metabolites in vivo, although progress is being made in this area [107]. Our method thus assumes
that the topology of a given system is known and that the unknown set of concentrations exists in a
linear space of dimension n in which each species ci comprises a separate dimension (Figure 5.1C).
The ultimate goal of the method is to eﬃciently search this concentration space to ﬁnd a set of
values that, when combined with the ﬁxed topology, renders the full model consistent with known
resting states and experimental time-series data obtained by perturbation of the cell.
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Figure 5.1: Example structure of model topology, ODEs, and concentration space. (A) The model
topology deﬁnes the state transitions (arrows) and rate equations (f ) that determine how molecules
are interconverted. This example model is organized into three overlapping modules, with molecules
c3 and c5 each occurring in two modules. Corresponding (B) ODEs and (C) concentration space
for the example topology in panel A. Each of the 7 molecules occupies a separate linear dimension,
with each module comprising a subspace of the full 7-dimensional space. Modules that share a
common molecule have intersecting subspaces.
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5.3

Homeostasis and the steady-state assumption

A special situation arises when dc/dt = 0 in equation 5.2. Under these conditions, the model is
said to be at steady state, and the vector css is a steady-state solution to the system of ODEs.
If f contains nonlinear terms, there may be an inﬁnite number of steady-state solutions for the
system of ODEs [38]. This set of solutions occupies some nonlinear subspace of the concentration
space exempliﬁed in Figure 5.1C. To guarantee that nonzero steady-state solutions may be found,
the method requires the model topology (and all module topologies) to be balanced, meaning that
the production and consumption of each molecule must be equal so that the total mass of the
system is conserved. This steady-state assumption [88] is a common constraint in stoichiometric
modeling and metabolic ﬂux analysis and is conceptually related to the biological phenomenon
of homeostasis [68], in which opposing processes are coordinated to maintain the stability of a
cell or organism. For example, a nerve cell may maintain a constant electrochemical gradient by
continually transporting ions across a lipid membrane.

5.4

5.4.1

Results and Discussion

Reduction of Modular Kinetic Networks

The ﬁrst phase of the method involves generating a compact representation of the steady-state
solutions for each module. The steps for module reduction are outlined in Figure 5.2A. First,
conservative bounds are chosen for c based on physiological and practical considerations. For
example, a regulatory enzyme is expected be present in at least one copy per cell and not to exceed
an intracellular concentration of one molar. Knowledge about the physical size of the system is
useful in this step to convert a raw copy number to a concentration. For small systems, this
information can provide a rigid lower bound on unknown concentrations (see Chapter 4). For
example, a single molecule in a 6 fL platelet has a concentration of 4 nM. Also, because molecular
concentrations can span several orders of magnitude, it is often more eﬃcient to delineate this range
of values on a logarithmic scale rather than a linear scale.
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Figure 5.2: Steps in dimensionality reduction of steady-state modules and example from platelet signaling
model. (A) Steps in dimensionality reduction of kinetic modules: (1) Restrict value ranges for each ci to
physiologically realistic ranges. (2) Compute multiple steady-state solutions to the model ODEs using initial
guesses sampled randomly from the deﬁned distribution. (3) Reduce the dimensionality of the steady-state
solution set by PCA. (B) Results obtained from modular reduction 4 kinetic modules in a platelet signaling
model. For each module, a ﬁxed topology was combined with initial guesses from the deﬁned distribution
and simulated until equilibrium was reached (dc/dt < 10−18 ) using 109 initial guesses for c0 . Speciﬁc
concentrations within these steady-state solutions were compared to experimentally measured values, and
solutions with low error (±10% of known concentration values) for these elements were selected as “points”
in the steady-state concentration space. PCA was then applied to transform these points to a new coordinate
set that maximally covers the space of steady-state solutions.
Once the sampling distribution for c has been deﬁned, steady-state solutions (css ) for each module are calculated using ﬁxed kinetic parameters for each reaction in the module obtained from
the literature [10, 108, 152], novel kinetic experiments, or estimation. For this step, each initial
guess is sampled from the distribution for c and combined with the predetermined topology. The
combination of ﬁxed rate equations, ﬁxed parameters, and forms a well-posed initial value problem,

dc
= f (t, c), c(t0 ) = c0
dt

(5.3)

that may be computed using a numerical solver [34]. For non-oscillating systems, steady-state
solutions may be obtained by simulating the system until equilibrium is reached (i.e., until dc/dt ≈
0). Alternatively, one may use any number of multidimensional root-ﬁnding routines, such as those
available in the GNU Scientiﬁc Library [58], to ﬁnd the closest n-dimensional root to the vector
function f using starting guess c0 .
In the third step, a large collection of steady-state solutions for each module is subjected to principal
component analysis (PCA). A sample size of 1000 points per unknown concentration is generally
suﬃcient to minimize error due to over-ﬁtting [62]. PCA is then used to transform these points
to a new coordinate set that optimally covers the space of steady-state solutions using the fewest
number of dimensions. For example, if two molecule concentrations in the steady-state space are
highly correlated due to participation in the same reaction, PCA will locate a single dimension
to represent each pair of points in the transformed space. Ultimately, these new dimensions will
be combined across all modules to search for global solutions that lie in the steady-state space
for the fully combined network. Since PCA is a linear method, a steady-state solution space
that is highly nonlinear may require more principal component vectors to accurately estimate the
solutions. Nonlinear methods of dimensionality reduction, such as kernel PCA [96] or local linear
embedding [134], may provide a more compact representation of steady-state solutions spaces in
future iterations of the method.
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The reduction procedure is illustrated with an example of a human platelet model comprising 4
interlinked signaling modules (Figure 5.2B). For each module, we used published reaction mechanisms and kinetic parameters to construct the module topologies [129]. Each topology was held
ﬁxed while the unknown CVs were sampled from empirically-deﬁned distributions. For this step,
we generated more than 109 sets of initial guesses (c0 ) for each module, computed the initial value
problem for each c0 until a steady state was reached (dc/dt ≈ 0), and selected only those steadystate CVs (css ) that were consistent with known concentrations. For example, the concentration
of intracellular Ca2+ ([Ca2+ ]i , Figure 5.2B) in platelets is known to be 1̃00 nM. Thus, only those
with [Ca2+ ]i ≈ 100 nM were kept as part of the steady-state solution space for the Ca2+ balance
module. This procedure was used to generate 10,000 steady state solutions for each module for
subsequent reduction by PCA. A minimal set of principal component (PC) vectors (those capturing
90% or more of the variance in the solution set) were used as search directions in the ﬁnal estimation
step, in which the transient behavior of the perturbed steady-state was compared to experimental
time-series data.
Interestingly, only a small fraction of initial guesses produce steady-state solutions that are also
consistent with known concentration values. For example, it was previously shown that only 50,000
of 109 initial guesses (0.005%) in the Ca2+ balance module (Figure 5.2B) met both requirements
and were suitable for further analysis [129]. Among this set of CVs, marginal distributions for
individual molecules were often conﬁned to a narrow range of values. As an example, 80% of
steady-state solutions for the calcium module contained ¡1000 IP3 molecules/cell, although initial
guesses were sampled uniformly between 1 and 106 molecules/cell. This observation shows that
the kinetic topology of these molecular networks places very strong constraints on the range of
concentrations that can exist at steady state. In biological terms, this suggests that ﬁxed kinetic
properties at the molecular level (e.g., IP3R and SERCA kinetics) can aﬀect not only the dynamical
features of a biochemical system but can also determine the abundance of chemical species and the
compartmental structures that contain them.

5.4.2

Merging Steady-State Modules

In the ﬁnal step of the method, the full model is assembled by combining PCA-reduced, steadystate solution spaces from each module into a combined steady-state solution space for the entire
system (Figure 5.3A). This global space is searched for full-length, steady-state solution vectors
that satisfy both the individual steady-state requirements of each module and the desired timedependent properties when the steady-state is perturbed (for example, by increasing the initial
concentration of a signaling molecule). For the platelet signaling model, consisting of 77 reactions,
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132 ﬁxed kinetic parameters, and 70 species [129], a set of 16 PC vectors representing all 72
unknown variables (70 molecule concentrations, 1 compartment size, and 1 rate constant) in the
model were used as search directions in a global optimization routine. The global solution space
was searched for models with accurate dynamic behavior using experimental time-series data for
ADP-stimulated Ca2+ release (Figure 5.3A). Equality constraints are imposed during optimization
to maintain consistent concentrations of molecules that are present in more than one module.
Speciﬁcally, for a steady-state space A represented by m PC vectors and a steady-state space B
represented by n PC vectors, the projections of each space onto must be equal,

Aci = Bci

(5.4)

where ci is the unit vector for the shared molecule, ci . This condition forms a linearly-constrained
optimization problem for which a number of eﬃcient routines exist [127]. We used the Asynchronous
Parallel Pattern Search (APPSPACK) to perform a derivative-free optimization of the platelet
signaling model [61]. A least-squares objective function was used to score the diﬀerence between
simulated (after perturbation of steady state) and experimental time-series data points. One of
the high-scoring steady-state solution vectors for the full model is shown in Figure 5.3B, along
with individual steady-state vectors for each of the four modules. This 72-dimensional vector (i)
satisﬁes the homeostasis constraint in that it is a steady-state solution, (ii) is consistent with the
known steady-state levels for 8 of the molecules in the 72-dimensional space, and (iii) predicts the
entire dynamic Ca2+ and IP3 response of platelets exposed to ADP (0100 μM). Additionally, rigid
and ﬂexible nodes (steady-state concentrations) in this 72-dimensional space were readily identiﬁed
when a set of allowable steady-state solution vectors are compared [129].

5.4.3

Applying the Method To Monitor Cellular Resting States

Resting systems remain in a steady state by the coordinated action of opposing but balanced
kinetic processes. Thus, in general, altering one ore more of these rate processes (e.g., increasing
the catalytic rate of a reaction) should upset the balance of the system and cause it to adopt
a new steady state. Various cell types have been shown to have altered steady-state properties
because of mutations that aﬀect the constitutive rates of reactions. For example, patients with
type 1 diabetes harbor more Ca2+ ATPase activity in their platelets than healthy volunteers and
experience high resting levels of intracellular Ca2+ [24]. In a separate case, a mutation within the
tyrosine kinase domain of epidermal growth factor receptor causes signiﬁcantly higher basal (growth
factor-independent) tyrosine phosphorylation levels than the wild-type receptor [26]. Therefore, to
examine the changes in steady-state properties caused by kinetic perturbations in our example
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Figure 5.3: Assembly of full model from steady-state modules. (A) The full model is assembled by
combining PCA-reduced, steady-state solution spaces from each module into a combined steadystate solution space. This global space is searched for full-length, steady-state solution vectors
that satisfy both the steady-state requirements of each module and the desired time-dependent
properties when the steady-state is perturbed (in this example, by increasing the concentration
of the signaling molecule ADP and measuring the change in intracellular Ca2+ concentration). A
simple linear constraint is imposed for every pair of modules that share a common molecule ci to
ensure that steady-state solutions are consistent. (B) To assemble the platelet signaling model,
a set of 16 PC vectors representing all 72 unknown variables in the model were used as search
directions in a global optimization routine. The global solution space was searched for models with
accurate dynamic behavior using experimental time-series data for ADP-stimulated Ca2+ release.
Species are grouped according to compartment. Color values correspond to molar concentrations
(mol/L or mol/m2 ) or as indicated: ∗ DTS species (mol L-1 ). † Extracellular species (mol L-1 ). ‡
DTS volume (L). § PM leak conductance/area (S m-2 ).
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model, we altered the rates of 3 important regulatory reactions and observed the system response
to each perturbation. Each perturbation cause a brief adjustment phase lasting 2̃00 s followed by
a more gradual phase characterized by a new steady-state proﬁle (Figure 5.4, left ). After 1 hr
of simulated time, steady-state concentrations and reaction ﬂuxes were quantiﬁed relative to their
original steady-state levels (Figure 5.4, right ).
As expected, increasing the rate of Ca2+ release from intracellular stores resulted in higher cytosolic
Ca2+ levels (7-fold increase) and 10-fold greater pumping activity by plasma membrane Ca2+ pumps
(PMCA), although the new steady-state Ca2+ release ﬂux remained relatively unchanged (Figure

5.4.4

Method Application, Computational Eﬃciency, and Extensions

We have presented a novel strategy for enumerating permissible steady-state solutions to ﬁxed
kinetic topologies and combining these solutions spaces to form large kinetic models. This is a
practical strategy because kinetic parameters are commonly reported whereas absolute concentrations are not (see, for example, refs. [10, 108, 152]). The method extends the capability to build
“genome-scale” models [50, 53, 70, 81] to include nonlinear kinetic features. Through application of
the method, we have also explored the implicit restrictions on steady-state solutions that can be
imposed by the underlying kinetic structures within a system [13]. This is useful from a physiological standpoint since the regulation and distribution of molecular species in living systems is largely
regulated by the coordinated action of synthetic, degrading, and transporting enzymes.
The proposed method requires the model to fulﬁll a steady-state assumption (i.e., the model must
contain nontrivial steady states) even if the system is typically characterized by transient behavior.
It is precisely this requirement that allows the model to have the dual functional behavior observed
in many biological contexts, such as in cellular signaling responses. At very low levels of activating
signal, the model remains at rest by quenching the low level of activating signal through feedback
mechanisms or futile cycling. When activating signals are increased, the system responds with the
appropriate transient signaling behavior. As an example, a human platelet must remain quiescent
under normal circulating conditions, tolerating a number of ﬂuctuations in its surrounding chemical
and physical environment. In the presence of the appropriate stimulus, however, it must be able
to respond rapidly to bleeding conditions and trigger a precise program of molecular signaling
events. Developing a mathematical model that is consistent with two or more biological behaviors
is analogous to writing a single equations that has multiple solutions, each dependent on a given
set of initial conditions and parameter values.
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Figure 5.4: Shifts in steady-state proﬁles caused by kinetic perturbations. The steady-state
platelet model was perturbed by changing selected kinetic parameters (±10-fold) and simulating
for 1 h (left panels). After approaching a new steady state, the model concentrations and ﬂuxes
were determined relative to their original steady-state values and colored according to fold-change
(right panels). Green indicates no change (NC) relative to initial ﬂux/concentration. Red indicates
a relative increase and blue indicates a relative decrease. Note that the color scale in each panel
is normalized separately to maximize distinctions in fold change. New steady states were achieved
after a (A) 10-fold increase in Ca2+ release through open IP3 R channels [129], (B) 10-fold decrease
in PKC-mediated inhibition of PLC-β, and (C) 10-fold increase in PIP2 hydrolysis (10-fold increase
in kcat of hydrolysis). Reactions with perturbed rate constants are circled and correspond to
2+
reaction mechanisms from ref [145]. (A) Ca2+
dts → Cai , (B) PKC∗+PLC−β → PKC∗+pPKC−β,
(C) PLC − β ∗ +PIP2 → PLC − β ∗ +IP3 + DAG.
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Our approach diﬀers critically from metabolic ﬂux analysis and previous genome-scale metabolic
network reconstructions [50, 139] because it accommodates nonlinear terms that describe the dynamic behavior of each reaction in the system. Previous large-scale network reconstructions typically use a stoichiometry matrix to represent the gross ﬂux of metabolites in the system [88].
Here, we have preserved the mathematical form of each kinetic rate equations as reported in the
literature, allowing models to be built from existing data in a “bottom-up” fashion [70] while still
allowing calibration to whole-system experimental data. This feature will substantially improve
the accuracy of dynamical system simulation and parameter estimation.
Additional computational savings are provided through modularization. When estimating modules
of modest size (5 or less unknown concentrations), we use a brute-force Monte Carlo approach to
densely sample the feasible space of initial conditions. Larger networks (20 or more unknowns)
cannot be eﬃciently searched in this brute-force manner, but can be built piecewise by combining
subspaces of smaller size that have been densely sampled. Using the nave Monte Carlo approach,
estimating n free parameters is exponential in n. By dividing these parameters into k independent
networks, each with n/k free parameters, the estimation procedure becomes exponential in n/k
and thus more tractable. By assembling the entire system from smaller, more manageable kinetic
modules, data may be used to test the functionality of individual modules before incorporating
them into the entire system. In several cases, this approach was shown to oﬀer a substantial computational beneﬁt (e.g., reducing the global search space by over 10,000-fold) by simply requiring a
steady-state solution with known subcomponent values. The search space can be reduced further
by principal component analysis if there is correlation between free parameters within a module.
This was found to be the case for enzymes that have opposing regulatory roles; increasing the levels
in one enzyme required a similar increase in the other in order to preserve homeostasis. Lastly,
modules sharing common components must hold the same value for that component, which imposes
an additional constraint on the steady-state solutions (equation 5.4).
As presented, the method exploits known kinetic parameters to restrict unknown concentrations
due to kinetic interactions. However, the method is equally valid for estimating unknown kinetic
parameters and/or utilizing known concentrations. Both concentrations and kinetic parameters
appear indistinguishably as nonlinear terms in the ordinary diﬀerential equations that describe
the system (Figure 5.1B). Hence, it does not matter which types of values are known and which
are estimated; the procedure is valid for mixed or incomplete sets of unknown values. The use of
qualitative data may also be exploited by the method. For example, beginning with a large set of
steady-state solutions for a given module, the size of the set may be reduced by determining which
solutions in the set contain some qualitative behavior or function. In a previous application of the
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method [129], a set of 109 steady-state solutions representing calcium balance in a resting platelet
were divided into 3 groups, according to their qualitative response to increased IP3 concentration
(low, mild, and high response). Using this technique, the functional testing of steady-state modules
may be used to eliminate a large subset of the original steady-state solution set. As another example,
one may use data from a Western blot to establish the relative abundance between two proteins
in the model. This qualitative information may be used to ﬁlter the steady-state solutions to a
reduced set that is consistent with experimental results. This kinetically-driven, constraint-based
approach, which combines a homeostasis requirement with known kinetic parameters and cellular
concentrations, naturally enforces numerical limits on unknown system quantities.
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Chapter 6

Conclusions and Future Directions
6.1

Summary of Results

The central theme of this work is the integration of complex data sets and mathematical modeling
to understand and predict intracellular signaling responses. We have used a variety of mathathematical methods—including ordinary diﬀerential equation modeling, principal component analysis, stochastic markov processes, artiﬁcial neural networks, digital image processing, and numerical optimization—to better understand the mechanistic basis of signaling in both growth factorresponsive cells and in human platelets. Our analyses have not only duplicated known signaling
behaviors in these cell types, but have also predicted and conﬁrmed new behvaviors.
In Chapter 2, we sought to understand how mutations that change the kinetic properties of the
tyrosine kinase domain of the EGFR can aﬀect the cell’s survival response. This was accomplished
by monitoring changes in two downstream signaling proteins, ERK and Akt, which showed disproportionate levels of activation in cells bearing mutated receptors. Chapter 3 extended this analysis
by studying the eﬀect of tyrosine kinase inhibitors on both receptor behavior and downstream
responses. Speciﬁcally, a gain of signaling ﬂux through the PI3K/Akt pathway in EGFR L858R mutants was strongly downregulated when the mutant was exposed to the tyrosine kinase inhibitor,
erlotinib. Using a branched signaling model to quantify phosphorylation patterns in the EGF
receptor, we showed that the EGFR mutants had increased binding to tyrosine kinase inhibitors
(TKIs), enhanced phosphorylation of substrate tyrosine residues, and preferential activation of the
Akt signaling pathway, a critical pathway for cell growth, survival, and motility. Future computational and experimental studies will be necessary to pinpoint the exact molecular players that
mediate both this increased activation of Akt and the potent eﬃcacy of the inhibitor.
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In Chapter 4, we used a kinetic model of calcium and phosphoinositide regulation in human
platelets to study P2Y1 activation by adenosine diphosphate (ADP). The model accurately predicted: (1) steady-state resting concentrations for intracellular calcium, inositol 1,4,5-trisphosphate,
diacylglycerol, phosphatidic acid, phosphatidylinositol, phosphatidylinositol phosphate, and phosphatidylinositol 4,5-bisphosphate; (2) transient increases in intracellular calcium, inositol 1,4,5trisphosphate, and Gq-GTP in response to ADP; and (3) the volume of the platelet dense tubular
system. A more stringent test of the model involved stochastic simulation of individual platelets,
which display an asynchronous calcium spiking behavior in response to ADP. Simulations accurately reproduced the broad frequency distribution of measured spiking events and demonstrated
that asynchronous spiking was a consequence of stochastic ﬂuctuations resulting from the small volume of the platelet. The model also provided insights into possible mechanisms of negative-feedback
signaling, the relative potency of platelet agonists, and cell-to-cell variation across platelet populations. This integrative approach to platelet biology oﬀers a novel and complementary strategy to
traditional reductionist methods.
Both of these studies made extensive use of ordinary diﬀerential equations to describe the system
dynamics and relied on published kinetic parameters. Building on this modeling framework, Chapter 5 presented a new method for constructing large-scale kinetic networks. This method involved
building kinetic models in stepwise fashion, beginning with small “resting” subnetworks that are
combined to form larger networks with complex time-dependent behaviors. The key step in the
method is the enforcement of a “homeostasis requirement” on all subnetworks (dC/dt = 0), which
ensures that all species concentrations remain constant over time even though each species may
undergo a gradual turnover through coupled reactions. This constraint was shown to not only
reduced the computational cost of ﬁtting experimental time-series data, but also provided insight
into limitations on system concentrations and architecture. This strategy aﬀorded a biologically
intuitive framework for building large-scale kinetic models of steady-state cellular systems and their
dynamics.

6.2

Extensions and Future Work

The insights derived from these studies (which have employed a relatively modest collection of
signaling pathways and reaction steps) indicate that increased biological knowledge may be gained
by incorporating additional cellular processes to form larger and more complex models. In this
section, we outline some additional projects that extend both the numerical methods and biological
scope of the work presented in this dissertation.
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6.2.1

Extension: Modeling the Platelet Response to Combinatorial Agonists

As we have seen, the platelet activation response requires a precise program of molecular signaling
events, including the activation of multiple platelet surface receptors (G protein-coupled receptors, receptor tyrosine kinases, integrins), phospholipid hydrolysis, release of intracellular Ca2+ ,
cytoskeletal rearrangement leading to shape change, secretion of storage granules, and paracrine
signaling between platelets [17]. When one or more of these signaling mechanisms is perturbed by
genetic or exogenous factors [118], pathological thrombus formation can result [57].
It is important to note that—in the environment of a forming clot—platelets experience all of these
signaling cues at the same time. For example, the potent platelet activator thrombin activates the
G protein-couple receptors (GPCRs) PAR1 and PAR4 on the platelet surface; exposed collagen on
subendothelial tissue binds to the tyrosine kinase GPVI and integrin α2 β1 ; ADP and thromboxane
A2 (TxA2), which are both released from the storage granules of activated platelets, activate the
P2Y family of GPCRs or the TP receptors, respectively. Although it is well appreciated that
these signaling events occur simultaneously in vivo, most of our understanding of platelet biology
is based on studies that examine a single agonist in isolation. For example, Yee et al. [182] have
used agreggometry to phenotype normal donors and classify some as hyperreactive based on their
individual responsiveness to ADP, epinephrine, collagen, collagen-related peptide and ristocetin.
While these studies have been useful for characterizing the eﬀect of individual agonists and their
receptors, they fall short of capturing the highly heterogeneous and dynamic platelet environment
in ﬂowing blood. A better understanding of platelet function in vivo will require the simultaneous
measurement of multiple interacting signaling pathways.
To broach this challenge, we developed a high-throughput experimental platform that measures
the human platelet response to arbitrary combinations of 6 major agonists (Figure 6.1A,B). Agonists tested were: convulxin (GPIV activator), ADP, thromboxane analog (U46619), PAR1 agonist
peptide, PAR4 agonist peptide, and PGE2. The method yields high-resolution time-series measurements of intracellular calcium levels over the ﬁrst few minutes of platelet activation. Intracellular
calcium concentration is a logical choice for monitoring the platelet activation response because it is
the common result of most signaling pathways and is critical to many of the processes that control
activation, such as actin mobilization and integrin activation [150]. We ﬁrst tested the platelet
response to all pair-wise combinations of 6 agonists at 3 doses (0.1, 1, 10 × EC50 ). These 135 calcium traces trained a 2-layer neural network (NN) (Figure 6.1C) to successfully predict the platelet
response to sequential addition of agonists and all ternary combinations of convulxin, TRAP and
ADP (Figure 6.2A,D). The NN model also identiﬁed 45 conditions of 4, 5, and 6 agonists predicted
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to display a range of synergistic signaling (Figure 6.2B,C). These predictions were conﬁrmed experimentally (R = 0.88) and revealed 4 highly synergistic conditions of high U46619/PGE2 ratio
(Figure 6.2E), consistent with the known thrombotic risk of COX-2 therapy. Finally, we identiﬁed unique patterns of pairwise agonist synergy among 4 healthy donors, providing a functional
ﬁngerprint of each donor’s individual platelet phenotype. Pairwise Agonist Scanning (PAS) provides a sensitive, patient-speciﬁc experimental/computational platform for understanding how an
individual’s cells integrate multiple molecular signals.

6.2.2

Extension: Quantifying the role of store-operated calcium entry
in platelet signaling

The platelet model presented in Chapter 4 did not contain a description for extracellular calcium, which plays an important role in sustaining the intracellular calcium levels during activation.
Store-operated calcium entry (SOCE) is the process by which the depletion of Ca2+ from the endoplasmic reticulum activates Ca2+ entry through channels in the plasma membrane. SOCE has
recently emerged as an important mechanism for many cellular processes including growth, motility,
secretion, and gene expression [99]. This mechanism has also been detected in human platelets and
shown to be essential for pathological thrombus formation [18]. However, little is known about the
relative importance of SOCE in platelet Ca2+ signaling in response to soluble agonists. Platelets
provide an ideal test system to study SOCE in vivo since they are easily obtained from healthy
donors and may be readily assayed for intracellular Ca2+ using ﬂuorogenic dyes. A full description
of platelet Ca2+ regulation is necessary to understand the observed correlations between platelet
Ca2+ handling and thrombus formation [18], diabetes [166] and hypertension [47].
Extending our work in Chapter 4, a kinetic model of SOCE, calibrated to measurements of Ca2+
release from internal and external platelet stores, could be used to predict dysfunctional Ca2+
ﬂux in thrombosis. Experimentally, the relative contribution of extracellular Ca2+ to the platelet
activation response may be quantiﬁed using a small panel of platelet agonists. The concentration of
free extracellular Ca2+ may be manipulated by adjusting the concentration of EDTA in the medium.
Time-course measurements of intracellular Ca2+ release will be generated for 3 major physiological
agonists: thrombin, ADP, and collagen-related peptide. For each agonist, diﬀerences among these
traces will show how intracellular calcium levels depend on the amount of extracellular calcium
that enters the platelet via SOCE. One may then construct an ODE-based model that quantiﬁes
the role of SOCE in platelet calcium signaling (Figure 6.3). Building upon the existing platelet
model, additional mechanisms for thrombin and collagen receptors as well as SOCE may be added.
Suﬃcient kinetic data exists to construct the model. For example, store-operated channel activation
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was recently related to luminal Ca2+ concentration in human Jurkat leukaemic T cells [136]. These
kinetic measurements will be used to supply an inward calcium current into the cytosol of the
platelet model as calcium in the platelet internal stores is depleted.

6.2.3

Future Work : A signal processing model to predict apoptotic response

Cellular signaling networks may be probed experimentally by changing molecular “inputs” (e.g.,
the concentration of an activating ligand) and recording molecular outputs (e.g., a change in gene
expression). The obvious challenge is to determine the processing “logic” [20] that occurs in between these experimental endpoints. Accomplishing this goal in a laboratory would require the
spatial and temporal measurement of all of the molecular participants in a signaling response—a
task that is clearly intractable using current methods of experimental analysis. An alternative
strategy is to develop a computer simulation of the signaling system of interest, hoping that the
simulation is accurate enough to reasonably approximate the true behavior of the system. Using an
accurate simulation of signaling, one may harness the powerful analytical capability of numerical
methods to slow down, speed up, perturb, calculate and analyze the quantitative elements in these
systems, aﬀording extended knowledge about how individual molecules interact to produce a signal.
Various modeling strategies have been used to predict cellular responses to molecular signaling. Ordinary diﬀerential equation models [38] provide excellent mechanistic detail but require extensive
knowledge of network topology and kinetic rate parameters. “Data-driven” approaches [74] such
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as clustering, principal component analysis, and partial least squares regression can derive useful biological insights from large data sets [71] but do not incorporate information about network
topology. Alternatively, artiﬁcial neural networks (NNs) oﬀer a ﬂexible framework for modeling
cellular signal networks and contain both topological and time-dependent features. We recently
trained a recurrent NN model to learn the platelet calcium response to all pair-wise combinations
of 6 platelet agonists at 3 doses (Figure 6.4A-B).
To determine whether a NN model can predict cytokine-induced apoptotic response and indentify important functional interactions within the signaling network, we can train a collection of
recurrent NN models to predict existing time-course measurements [72] of 19 apoptotic proteins
in response to 3 molecular stimuli (tumor necrosis factor, epidermal growth factor, and insulin).
By generating a large number of random network topologies, we will search for common features
that appear in most of the high-scoring network structures (Figure 6.4C). A similar technique,
Bayesian network inference [122], was used to reconstruct causal inﬂuences in human primary T
cell signaling [136]. Our choice of using a recurrent NN, however, is novel and oﬀers two important
advantages over Bayesian methods in that it allows cyclical structures (e.g., negative feedback)
and time-dependence in the model. This aim will provide a time-dependent model of cell survival
responses (e.g., nuclear fragmentation) to 3 cytokines and identify gross features of the network
that processes these molecular signals. To quantify the network response to perturbation, the interaction of pharmacological agents with the NN will be modeled by performing a sensitivity analysis
on the “consensus” NN structures identiﬁed in the training step. For example, by eliminating a
single node or edge in the apoptotic network, one can examine the network’s survival response and
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thereby quantify the impact of each perturbation to the NN. This analysis will identify speciﬁc
components of the network that may be targeted for rational drug design.

6.2.4

Future Work : Predicting global regulators of transcription in
“oncogene-addicted” cell lines

Mutations that aﬀect cell signaling can cause diﬀerences in basal gene expression [14]. For example,
mutations in the tyrosine kinase domain of EGFR (e.g., EGFRL834R) can cause distinct patterns
of gene expression [26] and are associated with sensitivity to tyrosine kinase inhibitors (TKIs) [35].
Statistical methods such as principal component analysis have been used to identify disrupted
signaling pathways based solely on expression signatures [173]. While this approach is useful for
placing mutant cells into previously known categories, there are currently no methods for predicting
the signaling mechanisms that regulate transcription based on entirely new gene expression proﬁles.
Such a method could be used to identify the upstream events that cause these diﬀerential expression
signatures and predict novel drug targets.
Here, statistical and graph-theoretical methods can be used to predict upstream signaling events
that cause changes in global gene expression for TKI-sensitive cell lines (e.g., H3255 with EGFRL834R ).
To identify programs of transcription factor (TF) regulation, we can extend a simple approach [167]
in which the abundances of known binding motifs in the upstream sequence of diﬀerentially expressed genes are used to determine a probable set of transcription factors responsible for generating
the observed expression proﬁle (Figure 6.5A). Focusing on a set of TKI-sensitive cell lines [35], we
will incorporate a conﬁdence score for each diﬀerentially expressed gene to weight the estimation
of enriched TF binding sites. This Bayesian approach will aﬀord a more powerful prediction of TF
activation by incorporating all of the information obtained from microarray analysis. Speciﬁcally,
we will calculate for each TF the probability that it is overrepresented in the data set:

P rob(Hi |D) =

(πi P rob(D|Hi )
j πj P rob(D|Hj )

(6.1)

The probability that TFi binding sites are overrepresented (Hi ) in the data is weighted by πi , a
conﬁdence value for each gene that contains binding sites for TFi . Predictions are validated by TF
protein arrays (Figure 6.5B). This aim will provide a ranked list of TFs that are similarly regulated
in a pool of TKI-sensitive cell lines.
To predict upstream transcriptional regulators, publically available databases of protein-protein
interactions (e.g., IntAct [84]) will be used to construct an in silico signaling network (a directed
graph) that also includes the TFs identiﬁed in the previous step. Subnetwork structures within the
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full graph are identiﬁed that most likely explain the calculated changes TF activities (Figure 6.5C).
Beginning with the TF nodes, a recursive algorithm performs a breadth-ﬁrst search along neighboring edges and assigns a score to each node based on the consistency between the known interaction
(activating or inhibiting) and the TF activity. Predictions are validated by RNAi [20].

6.3

Future Outlook

Systems biology—the discipline of integrating complex data sets to understand and discover the
molecular basis of emergent properites of biological systems—is nearly a decade old but still in a
nascent state. To truly advance our understanding of complex cellular systems and derive highimpact clinical applications using this approach, the ﬁeld requires a new suite of computational
tools and creative experimental strategies. The single greatest asset of all computational methods
is the ability to perform simple arithmetic in a very short period of time. Thus, to the extent
that signaling networks can be represented as a series of elementary calculations that describe the
dynamics of the system (e.g., ODEs that describe catalytic steps in an enzyme pathway), numerical
methods oﬀer a technological beneﬁt that is not directly accesible to the unaided human brain. The
grand challenge for systems biologists, however, will be to more clearly deﬁne which problems to
solve, how they may be cast in mathemtical terms, and—most importantly—how to interpret the
solutions. The work presented in this dissertation illustrates how novel computational strategies
can be used to derive meaningful insight from two mammalian signaling systems with important
clinical implications. At the very least, these analyses may serve as a starting point for future
investigation of signaling systems from a computational systems perspective.
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